PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT

Representative XRD pattern for the crystalline form of the compound (I-S)

FIG. 1

The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report
PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application 60/971,067, filed on September 10, 2007; and U.S. Provisional Application 61/018,822 filed on January 3, 2008, which are incorporated by reference herein in their entirety.

FIELD OF THE INVENTION

The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

BACKGROUND OF THE INVENTION

Diet therapy and exercise therapy are essential in the treatment of diabetes mellitus. When these therapies do not sufficiently control the conditions of patients, insulin or an oral antidiabetic agent is additionally used for the treatment of diabetes. At the present, there have been used as an antidiabetic agent biguanide compounds, sulfonylurea compounds, insulin resistance improving agents and α-glucosidase inhibitors. However, these antidiabetic agents have various side effects. For example, biguanide compounds cause lactic acidosis, sulfonylurea compounds cause significant hypoglycemia, insulin resistance improving agents cause edema and heart failure, and α-glucosidase inhibitors cause abdominal bloating and diarrhea. Under such circumstances, it has been desired to develop novel drugs for treatment of diabetes mellitus having no such side effects.

Recently, it has been reported that hyperglycemia participates in the onset and progressive impairment of diabetes mellitus, i.e., glucose toxicity theory. Namely, chronic hyperglycemia leads to decrease of insulin secretion and further to decrease of insulin sensitivity, and as a result, the blood glucose concentration is increased so that diabetes mellitus is self-exacerbated [cf., Diabetologia, vol. 28, p. 119 (1985); Diabetes Care, vol. 13, p. 610 (1990),...
etc.]. Therefore, by treating hyperglycemia, the aforementioned self-exacerbating cycle is interrupted so that the prophylaxis or treatment of diabetes mellitus is made possible.

As one of the methods for treating hyperglycemia, it is considered to excrete an excess amount of glucose directly into urine so that the blood glucose concentration is normalized. For example, by inhibiting sodium-dependent glucose transporter being present at the proximal convoluted tubule of kidney, the re-absorption of glucose at the kidney is inhibited, by which the excretion of glucose into urine is promoted so that the blood glucose level is decreased. In fact, it is confirmed that by continuous subcutaneous administration of phlorizin having SGLT inhibitory activity to diabetic animal models, hyperglycemia is normalized and the blood glucose level thereof can be kept normal for a long time so that the insulin secretion and insulin resistance are improved [cf., Journal of Clinical Investigation, vol. 79, p. 1510 (1987); ibid., vol. 80, p. 1037 (1987); ibid., vol. 87, p. 561 (1991), etc.].

In addition, by treating diabetic animal models with SGLT inhibitory agents for a long time, insulin secretion response and insulin sensitivity of the animals are improved without incurring any adverse affects on the kidney or imbalance in blood levels of electrolytes, and as a result, the onset and progress of diabetic nephropathy and diabetic neuropathy are prevented [cf., Journal of Medicinal Chemistry, vol. 42, p. 5311 (1999); British Journal of Pharmacology, vol. 132, p. 578 (2001), Ueta, Ishihara, Matsumoto, Oku, Nawano, Fujita, Saito, Arakawa, Life Sci., in press (2005), etc.].

From the above, SGLT inhibitors may be expected to improve insulin secretion and insulin resistance by decreasing the blood glucose level in diabetic patients and further prevent the onset and progress of diabetes mellitus and diabetic complications.

**SUMMARY OF THE INVENTION**

The present invention is directed to a process for the preparation of compounds of formula (I)
wherein Ring A and Ring B are one of the followings:

(1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or

(2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or

(3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety -Y-(Ring B) are both on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;

X is a carbon atom;

Y is -(CH$_2$)$_n$- wherein n is 1 or 2;

provided that in Ring A, X is part of an unsaturated bond;

or a pharmaceutically acceptable salt thereof, or a prodrug thereof; comprising
reacting a compound of formula (V) with a compound of formula (VI-S), in the presence of an alkyl lithium, in an organic solvent, at a temperature in the range of from about 0°C to about -78°C; to yield the corresponding compound of formula (VII);

reacting the compound of formula (VII) with BF₃OEt₂, in the presence of a thalkylsilane, in an organic solvent, to yield the corresponding compound of formula (VIII);

reacting the compound of formula (VIII) with acetic anhydride or acetyl chloride, in the presence of an organic base, neat or in an organic solvent, to yield the corresponding compound of formula (IX); and
In an embodiment, the present invention is directed to a process for the preparation of a compound of formula (I-S)

\[
\text{CH}_3 \quad \begin{array}{c}
\text{CH}_3 \\
\text{F} \\
\text{OH}
\end{array} \\
\text{OH} \quad \text{OH} \\
\text{OH}
\]

or a pharmaceutically acceptable salt thereof; (also known as 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene);

comprising
reacting a compound of formula (V-S), with a compound of formula (VI-S), in the presence of an alkyl lithium, in an organic solvent, at a temperature in the range of from about 0°C to about -78°C, to yield the corresponding compound of formula (VII-S);

reacting the compound of formula (VII-S) with BF₃OEt₂, in the presence of a trialkysilane, in an organic solvent, to yield the corresponding compound of formula (VIII-S);
reacting the compound of formula (VIII-S) with acetic anhydride or acetyl chloride, in the presence of an organic base, neat or in an organic solvent, to yield the corresponding compound of formula (IX-S); and

de-protecting the compound of formula (IX-S) to yield the corresponding compound of formula (I-S).

The present invention is further directed to a process for the recrystallization of a compound of formula (I-S). In an embodiment of the present invention, the compound of formula (I-S) is recrystallized from a mixture of ethyl acetate and water, using heptane as an anti-solvent.

The present invention is further directed to a crystalline form of the compound of formula (I-S)

characterized by the powder X-ray diffraction pattern peaks as herein described. In an embodiment, the present invention is directed to a crystalline form of the compound of formula (I-S) prepared by recrystallizing a compound of formula (I-S) from a mixture of ethyl acetate and water, and using heptane as an anti-solvent.
In another embodiment, the present invention is directed to a process for the preparation of a compound of formula (I-K)

![Chemical structure of (I-K)](image)

or a pharmaceutically acceptable salt thereof; (also known as 1-((β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene) comprising

![Chemical structures of (V-K), (VI-S), and (VII-K)](images)

reacting a compound of formula (V-K), with a compound of formula (VI-S), in the presence of an alkyl lithium, in an organic solvent, at a temperature in
the range of from about $0^\circ$C to about $-78^\circ$C, to yield the corresponding compound of formula (VII-K);

\[
\begin{align*}
\text{Cl} & \quad \text{O} \\
\text{OH} & \quad \text{HO} \\
\text{OTMS} & \quad \text{TMS}
\end{align*}
\]

(VII-K)

\[
\begin{align*}
\text{Cl} & \quad \text{O} \\
\text{OH} & \quad \text{HO} \\
\text{OH} & \quad \text{OH}
\end{align*}
\]

(X-K)

deprotecting the compound of formula (VII-K), to yield the corresponding compound of formula (X-K);

\[
\begin{align*}
\text{Cl} & \quad \text{O} \\
\text{OH} & \quad \text{HO} \\
\text{OH} & \quad \text{OH}
\end{align*}
\]

(X-K)

\[
\begin{align*}
\text{Cl} & \quad \text{O} \\
\text{OH} & \quad \text{HO} \\
\text{OH} & \quad \text{OH}
\end{align*}
\]

(VIII-K)

reacting the compound of formula (X-K) with BF$_3$OEt$_2$, in the presence of a thalkylsilane, in an organic solvent, to yield the corresponding compound of formula (VIII-K);

\[
\begin{align*}
\text{Cl} & \quad \text{O} \\
\text{OH} & \quad \text{HO} \\
\text{OH} & \quad \text{OH}
\end{align*}
\]

(VIII-K)

\[
\begin{align*}
\text{Cl} & \quad \text{O} \\
\text{OH} & \quad \text{HO} \\
\text{OAc} & \quad \text{AcO}
\end{align*}
\]

(IX-K)
reacting the compound of formula (VIII-K) with acetic anhydride or acetyl chloride, in the presence of an organic base, neat or in an organic solvent, to yield the corresponding compound of formula (IX-K); and

\[
\begin{align*}
\text{(IX-K)} & \quad \text{AcO} \quad \text{O} \quad \text{OAc} \\
\text{Cl} & \quad \text{OAc} \quad \text{OAc} \\
\text{OH} & \quad \text{OH} \\
\text{HO} & \quad \text{HO} \\
\text{HO} & \quad \text{HO} \\
\text{HO} & \quad \text{HO} \\
\end{align*}
\]

de-protecting the compound of formula (IX-K) to yield the corresponding compound of formula (I-K).

The present invention is further directed to a crystalline form of the compound of formula (I-K)

\[
\begin{align*}
\text{(I-K)} & \quad \text{Cl} \quad \text{O} \quad \text{OAc} \\
\text{OH} & \quad \text{OH} \\
\text{HO} & \quad \text{HO} \\
\text{HO} & \quad \text{HO} \\
\text{HO} & \quad \text{HO} \\
\end{align*}
\]

or a pharmaceutically acceptable salt thereof; (also known as 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene), which crystalline form may be characterized by its powder X-ray diffraction pattern peaks, as herein described. In an embodiment, the present invention is directed to process for the preparation and / or isolation of the crystalline form of the compound of formula (I-K).

The present invention is further directed to a product prepared according to any of the processes described herein.
Illustrative of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the product prepared according to any of the processes described herein. An illustration of the invention is a pharmaceutical composition made by mixing the product prepared according to any of the processes described herein and a pharmaceutically acceptable carrier. Illustrating the invention is a process for making a pharmaceutical composition comprising mixing the product prepared according to any of the processes described herein and a pharmaceutically acceptable carrier.

Illustrative of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a crystalline form of the compound of formula (I-S) or a crystalline form of the compound of formula (I-K), as described herein. An illustration of the invention is a pharmaceutical composition made by mixing a crystalline form of the compound of formula (I-S) or a crystalline form of the compound of formula (I-K), as described herein and a pharmaceutically acceptable carrier. Illustrating the invention is a process for making a pharmaceutical composition comprising mixing a crystalline form of the compound of formula (I-S) or a crystalline form of the compound of formula (I-K), as described herein and a pharmaceutically acceptable carrier.

Exemplifying the invention are methods of treating a disorder mediated by SGLT (including treating or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension,) comprising administering to the subject in need thereof a therapeutically effective amount of any of the compounds, crystalline forms or pharmaceutical compositions described above.

Further exemplifying the invention are methods of treating type 1 and type 2 diabetes mellitus, comprising administering to a subject in need of treatment a therapeutically effective amount of any of the compounds, crystalline forms or pharmaceutical compositions described above, alone or in combination with at least one antidiabetic agent, agent for treating diabetic
complications, anti-obesity agent, antihypertensive agent, antiplatelet agent, anti-atherosclerotic agent and/or hypolipidemic agent.

**BRIEF DESCRIPTION OF THE FIGURE(S)**

Figure 1 illustrates a representative XRD pattern for the crystalline form of the compound of formula (I-S).

Figure 2 illustrates a representative X-ray powder diffraction pattern of the crystalline form of the compound of formula (I-K), as measured on an RINT-ULTIMA3, Rigaku, Tokyo, Japan X-ray diffractometer.

Figure 3 illustrates a representative X-ray powder diffraction pattern of the crystalline form of the compound of formula (I-K), as measured on an X-ray diffractometer X'Pert Pro MPD, Philips X-ray diffractometer. Figure 4 illustrates a representative infra-red spectrum of the crystalline of the compound of formula (I-K) in mineral oil.

Figure 5 illustrates a representative infra-red spectrum of the crystalline of the compound of formula (I-K) from a KBr pellet.

**DETAILED DESCRIPTION OF THE INVENTION**

The present invention is directed to a process for the preparation of compound of formula (I)

\[
\begin{align*}
\text{A} & \quad \text{Y} & \quad \text{B} \\
\text{X} & \quad \text{O} & \quad \text{OH} \\
\text{OH} & \quad \text{OH} & \quad \text{OH}
\end{align*}
\]

wherein X, Y, Ring A and Ring B are as herein defined. The compounds of the formula (I) exhibits an inhibitory activity against sodium-dependent glucose transporter being present in the intestine and the kidney of mammalian species, and is useful in the treatment of diabetes mellitus or diabetic complications such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, obesity, and delayed wound healing. One skilled in the art will
further recognize that any of the compounds or crystalline forms described herein may be used, if necessary, in combination with one or more of other anti-diabetic agents, antihyperglycemic agents and/or agents for treatment of other diseases; and may be administered in the same dosage form, or in a separate oral dosage form or by injection.

PCT Publication WO 2005/01 2326 discloses a class of compounds that are inhibitors of sodium-dependent glucose transporter (SGLT), including the compound of formula (I-K), also known as 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene, and the compound of formula (I-S), also known as 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene. PCT Publication WO 2005/01 2326 further discloses the use of said compounds, including the compound of formula (I-K) and the compound of formula (I-S), for the treatment of diabetes, obesity, diabetic complications, and the like.

The present invention is further directed to processes for the preparation of a compound of formula (I-S) or a pharmaceutically acceptable salt thereof; and a compound of formula (I-K) or a pharmaceutically acceptable salt thereof.

The present invention is further directed to a novel crystalline form of the compound of formula (I-S) and a novel crystalline form of the compound of formula (I-K), as herein described in more detail. The present invention is further directed to processes for the preparation of the crystalline forms of the compound of formula (I-S) and the compound of formula (I-K) as herein described in more detail.

The term "halogen atom" or "halo" means chlorine, bromine and fluorine, and chlorine and fluorine are preferable.

The term "alkyl group" means a straight or branched saturated monovalent hydrocarbon chain having 1 to 12 carbon atoms. The straight chain or branched chain alkyl group having 1 to 6 carbon atoms is preferable, and the straight chain or branched chain alkyl group having 1 to 4 carbon atoms is more preferable. Examples thereof are methyl group, ethyl group, propyl group, isopropyl group, butyl group, t-butyl group, isobutyl group, pentyl
group, hexyl group, isohexyl group, heptyl group, 4,4-dimethylpentyl group, octyl group, 2,2,4-trimethylpentyl group, nonyl group, decyl group, and various branched chain isomers thereof. Further, the alkyl group may optionally and independently be substituted by 1 to 4 substituents as listed below, if necessary.

The term "alkylene group" or "alkylene" means a straight or branched divalent saturated hydrocarbon chain having 1 to 12 carbon atoms. The straight chain or branched chain alkylene group having 1 to 6 carbon atoms is preferable, and the straight chain or branched chain alkylene group having 1 to 4 carbon atoms is more preferable. Examples thereof are methylene group, ethylene group, propylene group, trimethylene group, etc. If necessary, the alkylene group may optionally be substituted in the same manner as the above-mentioned "alkyl group". Where alkylene groups as defined above attach at two different carbon atoms of the benzene ring, they form an annelated five, six or seven membered carbocycle together with the carbon atoms to which they are attached, and may optionally be substituted by one or more substituents defined below.

The term "alkenyl group" means a straight or branched monovalent hydrocarbon chain having 2 to 12 carbon atoms and having at least one double bond. Preferable alkenyl group is a straight chain or branched chain alkenyl group having 2 to 6 carbon atoms, and the straight chain or branched chain alkenyl group having 2 to 4 carbon atoms is more preferable. Examples thereof are vinyl group, 2-propenyl group, 3-butenyl group, 2-butenyl group, 4-pentenyl group, 3-pentenyl group, 2-hexenyl group, 3-hexenyl group, 2-heptenyl group, 3-heptenyl group, 4-heptenyl group, 3-octenyl group, 3-noneny group, 4-decenyl group, 3-undecenyl group, 4-dodecenyl group, 4,8,12-tetradecatrienyl group, etc. The alkenyl group may optionally and independently be substituted by 1 to 4 substituents as mentioned below, if necessary.

The term "alkylene group" means a straight or branched divalent hydrocarbon chain having 2 to 12 carbon atoms and having at least one double bond. The straight chain or branched chain alkenylene group having 2 to 6 carbon atoms is preferable, and the straight chain or branched chain
alkylene group having 2 to 4 carbon atoms is more preferable. Examples thereof are vinylene group, propenylene group, butadienylene group, etc. If necessary, the alkenylene group may optionally be substituted by 1 to 4 substituents as mentioned below, if necessary. Where alkenylene groups as defined above attach at two different carbon atoms of the benzene ring, they form an annelated five, six or seven membered carbocycle (e.g., a fused benzene ring) together with the carbon atoms to which they are attached, and may optionally be substituted by one or more substituents defined below.

The term "alkynyl group" means a straight or branched monovalent hydrocarbon chain having at least one triple bond. The preferable alkynyl group is a straight chain or branched chain alkynyl group having 2 to 6 carbon atoms, and the straight chain or branched chain alkynyl group having 2 to 4 carbon atoms is more preferable. Examples thereof are 2-propynyl group, 3-butynyl group, 2-butynyl group, 4-pentynyl group, 3-pentynyl group, 2-hexynyl group, 3-hexynyl group, 2-heptynyl group, 3-heptynyl group, 4-heptynyl group, 3-octynyl group, 3-nonylnyl group, 4-decynyl group, 3-undecynyl group, 4-dodecynyl group, etc. The alkynyl group may optionally and independently be substituted by 1 to 4 substituents as mentioned below, if necessary.

The term "cycloalkyl group" means a monocyclic or bicyclic monovalent saturated hydrocarbon ring having 3 to 12 carbon atoms, and the monocyclic saturated hydrocarbon group having 3 to 7 carbon atoms is more preferable. Examples thereof are a monocyclic alkyl group and a bicyclic alkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, cyclodecyl group, etc. These groups may optionally and independently be substituted by 1 to 4 substituents as mentioned below, if necessary. The cycloalkyl group may optionally be condensed with a saturated hydrocarbon ring or an unsaturated hydrocarbon ring (said saturated hydrocarbon ring and unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂ within the ring, if necessary), and the condensed saturated hydrocarbon ring and the condensed unsaturated hydrocarbon ring may be optionally and independently be substituted by 1 to 4 substituents as mentioned below.
The term "cycloalkylidene group" means a monocyclic or bicyclic
divalent saturated hydrocarbon ring having 3 to 12 carbon atoms, and the
monocyclic saturated hydrocarbon group having 3 to 6 carbon atoms is
preferable. Examples thereof are a monocyclic alkylidene group and a bicyclic
alkylidene group such as cyclopropylidene group, cyclobutylidene group,
cyclopentylidene group, cyclohexylidene group, etc. These groups may
optionally and independently be substituted by 1 to 4 substituents as mentioned
below, if necessary. Besides, the cycloalkylidene group may optionally be
condensed with a saturated hydrocarbon ring or an unsaturated hydrocarbon
ring (said saturated hydrocarbon ring and unsaturated hydrocarbon ring may
optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂
within the ring, if necessary), and the condensed saturated hydrocarbon ring
and the unsaturated hydrocarbon ring may be optionally and independently be
substituted by 1 to 4 substituents as mentioned below.

The term "cycloalkenyl group" means a monocyclic or bicyclic
monovalent unsaturated hydrocarbon ring having 4 to 12 carbon atoms and
having at least one double bond. The preferable cycloalkenyl group is a
monocyclic unsaturated hydrocarbon group having 4 to 7 carbon atoms.
Examples thereof are monocyclic alkenyl groups such as cyclopentenyl group,
cyclopentadienyl group, cyclohexenyl group, etc. These groups may optionally
and independently be substituted by 1 to 4 substituents as mentioned below, if
necessary. Besides, the cycloalkenyl group may optionally be condensed with
a saturated hydrocarbon ring or an unsaturated hydrocarbon ring (said
saturated hydrocarbon ring and unsaturated hydrocarbon ring may optionally
contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂ within the
ring, if necessary), and the condensed saturated hydrocarbon ring and the
unsaturated hydrocarbon ring may be optionally and independently be
substituted by 1 to 4 substituents as mentioned below.

The term "cycloalkynyl group" means a monocyclic or bicyclic
unsaturated hydrocarbon ring having 6 to 12 carbon atoms, and having at least
one triple bond. The preferable cycloalkynyl group is a monocyclic unsaturated
hydrocarbon group having 6 to 8 carbon atoms. Examples thereof are
monocyclic alkynyl groups such as cyclooctynyl group, cyclodecynyl group.
These groups may optionally be substituted by 1 to 4 substituents as mentioned below, if necessary. Besides, the cycloalkynyl group may optionally and independently be condensed with a saturated hydrocarbon ring or an unsaturated hydrocarbon ring (said saturated hydrocarbon ring and unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂ within the ring, if necessary), and the condensed saturated hydrocarbon ring or the unsaturated hydrocarbon ring may be optionally and independently be substituted by 1 to 4 substituents as mentioned below.

The term "aryl group" means a monocyclic or bicyclic monovalent aromatic hydrocarbon group having 6 to 10 carbon atoms. Examples thereof are phenyl group, naphthyl group (including 1-naphthyl group and 2-naphthyl group). These groups may optionally and independently be substituted by 1 to 4 substituents as mentioned below, if necessary. Besides, the aryl group may optionally be condensed with a saturated hydrocarbon ring or an unsaturated hydrocarbon ring (said saturated hydrocarbon ring and unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO or SO₂ within the ring, if necessary), and the condensed saturated hydrocarbon ring or the unsaturated hydrocarbon ring may be optionally and independently be substituted by 1 to 4 substituents as mentioned below.

The term "unsaturated monocyclic heterocyclic ring" means an unsaturated hydrocarbon ring containing 1-4 heteroatoms independently selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the preferable one is a 4- to 7-membered saturated or unsaturated hydrocarbon ring containing 1-4 heteroatoms independently selected from a nitrogen atom, an oxygen atom and a sulfur atom. Examples thereof are pyridine, pyrimidine, pyrazine, furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, 4,5-dihydrooxazole, thiazole, isothiazole, thiadiazole, triazole, tetrazole, etc. Among them, pyridine, pyrimidine, pyrazine, furan, thiophene, pyrrole, imidazole, oxazole, and thiazole can be preferably used. The "unsaturated monocyclic heterocyclic ring" may optionally and independently be substituted by 1-4 substituents as mentioned below, if necessary.
The term "unsaturated fused heterobicyclic ring" means hydrocarbon ring comprised of a saturated or an unsaturated hydrocarbon ring condensed with the above mentioned unsaturated monocyclic heterocyclic ring where said saturated hydrocarbon ring and said unsaturated hydrocarbon ring may optionally contain an oxygen atom, a nitrogen atom, a sulfur atom, SO, or SO2 within the ring, if necessary. The "unsaturated fused heterobicyclic ring" includes, for example, benzothiophene, indole, tetrahydrobenzothiophene, benzofturan, isoquinoline, thienothiophene, thienopyridine, quinoline, indoline, isoindoline, benzothiazole, benzoazole, indazole, dihydroisoquinoline, etc.

Further, the "heterocyclic ring" also includes possible N- or S-oxides thereof.

The term "heterocyclyl" means a monovalent group of the above-mentioned unsaturated monocyclic heterocyclic ring or unsaturated fused heterobicyclic ring and a monovalent group of the saturated version of the above-mentioned unsaturated monocyclic heterocyclic or unsaturated fused heterobicyclic ring. If necessary, the heterocyclyl may optionally and independently be substituted by 1 to 4 substituents as mentioned below.

The term "alkanoyl group" means a formyl group and ones formed by binding an "alkyl group" to a carbonyl group.

The term "alkoxy group" means ones formed by binding an "alkyl group" to an oxygen atom.

The substituent for the above each group includes, for example, a halogen atom (fluorine, chlorine, bromine), a nitro group, a cyano group, an oxo group, a hydroxy group, a mercapto group, a carboxyl group, a sulfo group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkynyl group, an aryl group, a heterocyclyl group, an alkoxy group, an alkenyloxy group, an alkynyloxy group, a cycloalkyloxy group, a cycloalkenyloxy group, a cycloalkynyloxy group, an aryloxy group, a heterocyclyloxy group, an alkanoyl group, an alkenylcarbonyl group, an alkynylcarbonyl group, a cycloalkylcarbonyl group, a cycloalkenylcarbonyl group, a cycloalkynylcarbonyl group, an arylicarbonyl group, a hetero-cyclylcarbonyl group, an alkoxy-carbonyl group, an alkenyloxy-carbonyl group, an alkynyloxy-carbonyl group, a cycloalkyloxy-carbonyl group, a cycloalkenyl-oxy-carbonyl group, a cyclo-
alkynyl-oxycarbonyl group, an arylxoxycarbonyl group, a heterocycloxyloxy carbonyl group, an alkanoyloxy group, an alkenyl-carbonyloxy group, an alkynyl-carbonyloxy group, a cycloalkyl-carbonyloxy group, a cycloalkenyl-carbonyloxy group, an arylcarbonyloxy group, a hetero-cyclyloxycarbonyl group, a n aryloxycarbonyl group, a heterocyclyloxycarbonyl group, a n alkanoyloxy group, a n alkenyl-carbonyloxy group, a cycloalkyl-thiocarbonyloxy group, a cycloalkynyl-carbonyloxy group, an arylcarbonyloxy group, a hetero-cyclylcarbonyloxy group, an alkylthio group, an alkenyl-thio group, an alkynylthio group, a cycloalkylthio group, a cycloalkenyl-thio group, a cycloalkynylthio group, an arylthio group, a heterocyclylthio group, an amino group, a mono- or di-alkyl-amino group, a mono- or di-alkanoylamino group, a mono- or di-alkoxy-carbonyl-amino group, a mono- or di-arylcarbonyl-amino group, an alkylsulfinylamino group, an alkyl-sulfonyl-amino group, an arylsulfinylamino group, an arylsulfonylamino group, a carbamoyl group, a mono- or di-alkyl-carbamoyl group, a mono- or di-arylcarbamoyl group, an alkylsulfinyl group, an alkenyl-sulfinyl group, an alkynylsulfinyl group, an alkynylsulfinyl group, a cycloalkyl-sulfinyl group, a cycloalkenylsulfinyl group, a cycloalkynyl-sulfinyl group, an arylsulfinyl group, a heterocyclyl-sulfinyl group, an alkyl-sulfonyl group, an alkenylsulfonyl group, an alkynylsulfonyl group, a cycloalkyl-sulfonyl group, a cycloalkenyl-sulfonyl group, a cycloalkynyl-sulfonyl group, an arylsulfonyl group, and a heterocyclylsulfonyl group. Each group as mentioned above may optionally be substituted by these substituents.

Further, the terms such as a haloalkyl group, a halo-lower alkyl group, a haloalkoxy group, a halo-lower alkoxy group, a halophenyl group, or a halo-heterocyclyl group mean an alkyl group, a lower alkyl group, an alkoxy group, a lower alkoxy group, a phenyl group or a heterocyclyl group (hereinafter, referred to as an alkyl group, etc.) being substituted by one or more halogen atoms, respectively. Preferable ones are an alkyl group, etc. being substituted by 1 to 7 halogen atoms, and more preferable ones are an alkyl group, etc. being substituted by 1 to 5 halogen atoms. Similarly, the terms such as a hydroxyalkyl group, a hydroxy-lower alkyl group, a hydroxyalkoxy group, a hydroxy-lower alkoxy group and a hydroxyphenyl group mean an alkyl group, etc., being substituted by one or more hydroxy groups. Preferable ones are an alkyl group, etc., being substituted by 1 to 4 hydroxy groups, and more preferable ones are an alkyl group, etc., being substituted by 1 to 2 hydroxy groups. Further, the terms such as an alkoxyalkyl group, a lower alkoxyalkyl
group, an alkoxy-lower alkyl group, a lower alkoxy-lower alkyl group, an alkoxyalkoxy group, a lower alkoxyalkoxy group, an alkoxy-lower alkyl group, an alkoxyalkoxy group, a lower alkoxy-lower alkyl group, an alkoxyphenyl group, and a lower alkoxyphenyl group means an alkyl group, etc., being substituted by one or more alkoxy groups. Preferable ones are an alkyl group, etc., being substituted by 1 to 4 alkoxy groups, and more preferable ones are an alkyl group, etc., being substituted by 1 to 2 alkoxy groups.

The terms "arylalkyl" and "arylalkoxy" as used alone or as part of another group refer to alkyl and alkoxy groups as described above having an aryl substituent.

The term "lower" used in the definitions for the formulae in the present specification means a straight or branched carbon chain having 1 to 6 carbon atoms, unless defined otherwise. More preferably, it means a straight or branched carbon chain having 1 to 4 carbon atoms.

The term "prodrug" means an ester or carbonate, which is formed by reacting one or more hydroxy groups of the compound of the formula I with an acylating agent substituted by an alkyl, an alkoxy or an aryl by a conventional method to produce acetate, pivalate, methylcarbonate, benzoate, etc. Further, the prodrug includes also an ester or amide, which is similarly formed by reacting one or more hydroxy groups of the compound of the formula I with an α-amino acid or a β-amino acid, etc. using a condensing agent by a conventional method.

The pharmaceutically acceptable salt of the compound of the formula I includes, for example, a salt with an alkali metal such as lithium, sodium, potassium, etc.; a salt with an alkaline earth metal such as calcium, magnesium, etc.; a salt with zinc or aluminum; a salt with an organic base such as ammonium, choline, diethanolamine, lysine, ethylenediamine, t-butylamine, t-octylamine, tris(hydroxymethyl)aminomethane, N-methyl glucosamine, triethanolamine and dehydroabietylamine; a salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or a salt with an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid,
maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, etc.; or a salt with an acidic amino acid such as aspartic acid, glutamic acid, etc.

The compound of the present invention also includes a mixture of stereoisomers, or each pure or substantially pure isomer. For example, the present compound may optionally have one or more asymmetric centers at a carbon atom containing any one of substituents. Therefore, the compound of the formula (I) may exist in the form of enantiomer or diastereomer, or a mixture thereof. When the present compound (I) contains a double bond, the present compound may exist in the form of geometric isomerism (cis-compound, trans-compound), and when the present compound (I) contains an unsaturated bond such as carbonyl, then the present compound may exist in the form of a tautomer, and the present compound also includes these isomers or a mixture thereof. The starting compound in the form of a racemic mixture, enantiomer or diastereomer may be used in the processes for preparing the present compound. When the present compound is obtained in the form of a diastereomer or enantiomer, they can be separated by a conventional method such as chromatography or fractional crystallization.

In addition, the present compound (I) includes an intramolecular salt, hydrate, solvate or polymorphism thereof.

Examples of the optionally substituted unsaturated monocyclic heterocyclic ring of the present invention include an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-5 substituents selected from the group consisting of a halogen atom, a nitro group, a cyano group, an oxo group, a hydroxyl group, a mercapto group, a carboxyl group, a sulf group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyl idenemethyl group, a cycloalkenyl group, a cycloalkynyl group, an aryl group, a heterocyclyl group, an alkoxy group, an alkenyloxy group, an alkynloxy group, a cycloalkyloxy group, a cycloalkoxy group, an arloxy group, a heterocyclyloxy group, an alkanoyl group, an alkenylcarbonyl group, an alkynylcarbonyl group, a cycloalkylcarbonyl group, a cycloalkenylcarbonyl group, a cycloalkynylcarbonyl group, a cycloalkynylcarbonyl group.
group, an arylcarbonyl group, a heterocyclylcarbonyl group, an alkoxy carbonyl
group, an alkenyloxycarbonyl group, an alkynyloxycarbonyl group, a
cycloalkyloxycarbonyl group, a cycloalkenyloxycarbonyl group, a
cycloalkynlyloxycarbonyl group, an arylloxycarbonyl group, a
heterocyclyloxycarbonyl group, an alkanoyloxy group, an alkenyloxycarboxyloxy
group, an alkynyloxycarboxyloxy group, a cycloalkyloxycarboxyloxy group, a
cycloalkenyloxycarboxyloxy group, an alkynlyloxycarboxyloxy group, a
cycloalkynlyloxycarboxyloxy group, an alkylthio group, an
alkynylthio group, an alkylthio group, a
cycloalkylthio group, a cycloalkynylthio group, an arythio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoylamino group, a mono- or di-alkoxy carbamoyl group, a
mono- or di-alkoxy carbamoyl group, an alkylsulfonylamino group, an
cycloalkylsulfonylamino group, an alkylsulfonylamino group, an arylsulfonylamino
group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, a mono- or di-
arylcyclylcarbamoyl group, an alkylsulfinyl group, an alkene sulfynyl group, an
alkynylsulfinyl group, a cycloalkylsulfinyl group, a cycloalkenylsulfinyl group, a
cycloalkynylsulfinyl group, an arylsulfinyl group, a heterocyclylsulfinyl group, an
cycloalkylsulfonyl group, an alkene sulfonyl group, an alkynylsulfonyl group, an
cycloalkylsulfonyl group, a cycloalkenylsulfonyl group, a cycloalkynylsulfonyl
group, an arylsulfonyl group, and a heterocyclylsulfonyl group wherein each
substituent may optionally be further substituted by these substituents.

Examples of the optionally substituted unsaturated fused heterobicyclic
ring of the present invention include an unsaturated fused heterobicyclic ring
which may optionally be substituted by 1-5 substituents selected from the group
consisting of a halogen atom, a nitro group, a cyano group, an oxo group, a
hydroxy group, a mercapto group, a carboxyl group, a sulfo group, an alkyl
group, an alkenyl group, an alkynyl group, a cycloalkyl group, a
cycloalkylidene- methyl group, a cycloalkenyl group, a cycloalkynyl group, an
aryl group, a heterocyclyl group, an alkoxy group, an alkenyloxy group, an
alkenyloxy group, a cycloalkyloxy group, a cycloalkenyloxy group, a
cycloalkynloxy group, an arloxy group, a heterocyclyloxy group, an alkanoyl
group, an alkenyl carbonyl group, an alkynyl carbonyl group, a
cycloalkylcarbonyl group, a cycloalkenyl- carbonyl group, a cycloalkynyl-
carbonyl group, a arylcarbonyl group, a heterocyclylcarbonyl group, an
alkoxycarbonyl group, an alkenyloxycarbonyl group, an alkyloxy- carbonyl
group, a cycloalkyloxycarbonyl group, a cycloalkenyloxy- carbonyl group, a
cycloalkynylcarbonyl group, a cycloalkynyl- carbonyl group, a
heterocyclyloxycarbonyl group, a heterocyclylcarbonyl group, an
alkanoyl group, an alkenylcarbonyl group, a alkynylcarbonyl group, a
arylcarbamoyl group, a carbamoyl group, a mono- or di-alkylamino group, a
mono- or di-alkylamino group, a mono- or di-alkynylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
an alkylthio group, a cycloalkylthio group, a cycloalkylthio group, an arylthio group, a
heterocyclylthio group, an amino group, a mono- or di-alkylamino group, a
mono- or di-alkanoyl- amino group, a mono- or di-alkoxycarbonylamino group,
a mono- or di-arylcycloalkenyl group, a cycloalkynylcarbonyl group, a cyclo-
alkynylcarbonyl group, a heterocyclyl- carbonyl group, a heterocyclyl-
carbonyl group, an alkylthio group,
cycloalkylcarbonyl group, a cycloalkenylcarbonyl group, a cycloalkynylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, an alkoxy carbonyl group, an alkenyloxycarbonyl group, an alkynyloxycarbonyl group, a cycloalkyl oxycarbonyl group, a cycloalkenyl oxycarbonyl group, a cycloalkynyl oxycarbonyl group, an arylcarbonyl group, a heterocyclyloxycarbonyl group, an alkoxycarbonyl group, an alkenyloxycarbonyl group, an alkynyloxycarbonyl group, an alkylthio group, an alkenylthio group, an alkynylthio group, an arylthio group, a heterocyclylthio group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, an aryl group, a heterocyclic group, a mono- or di-alkylamino group, a mono- or di-alkanoylamino group, a mono- or di-alkoxycarbonylamino group, a mono- or di-arylcarbonylamino group, an alkylsulfinylamino group, an alkylsulfonylamino group, an arylsulfinylamino group, an arylsulfonylamino group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, a mono- or di-arylcarbamoyl group, an alkylsulfinyl group, an aralkylsulfinyl group, an alkenylsulfinyl group, an alkynylosulfanyl group, a cycloalkylsulfinyl group, a cycloalkenylsulfinyl group, a cycloalkynylsulfinyl group, an arylsulfinyl group, a heterocyclylsulfinyl group, an alkylsulfonyl group, an alkenylsulfonyl group, a heterocyclylsulfonyl group, an alkylene group, an alkynleneoxy group, an alkenylenedioxy group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, an aryl group, a heterocyclic group, a mono- or di-alkylamino group, a mono- or di-alkanoylamino group, a mono- or di-alkoxycarbonylamino group, a mono- or di-arylcarbonylamino group, an alkylsulfinylamino group, an alkylsulfonylamino group, an arylsulfinylamino group, an arylsulfonylamino group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, a mono- or di-arylcarbamoyl group, an alkylsulfinyl group, an aralkylsulfinyl group, an alkenylsulfinyl group, an alkynylosulfanyl group, a cycloalkylsulfinyl group, a cycloalkenylsulfinyl group, a cycloalkynylsulfinyl group, an arylsulfinyl group, a heterocyclylsulfinyl group, an alkylsulfonyl group, an alkenylsulfonyl group, a heterocyclylsulfonyl group, an alkylene group, an alkynleneoxy group, an alkenylenedioxy group, and an alkenylene group wherein each substituent may optionally be further substituted by these substituents.

Moreover, examples of the optionally substituted benzene ring include a benzene ring substituted with an alkenyl group to form an annelated carbocycle together with the carbon atoms to which they are attached, and also includes a benzene ring substituted with an alkenylene group to form an annelated carbocycle such as a fused benzene ring together with the carbon atoms to which they are attached.

Preferable examples of the optionally substituted unsaturated monocyclic heterocyclic ring include an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents selected from the
group consisting of a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyldienemethyl group, a cycloalkenyl group, a cycloalkyloxy group, an aryl group, an arylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxy carbonylamino group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkanoyl group, an alkylsulfonylamino group, an arylsulfonylamino group, an alkylsulfanyl group, an alkylsulfonyl group, an arylsulfonyl group, a heterocyclic group, and an oxo group.

Preferable examples of the optionally substituted unsaturated fused heterobicyclic ring include an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents independently selected from the group consisting of a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyldienemethyl group, a cycloalkenyl group, a cycloalkyloxy group, an aryl group, an arylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxy carbonylamino group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkanoyl group, an alkylsulfonylamino group, an arylsulfonylamino group, an alkylsulfanyl group, an alkylsulfonyl group, an arylsulfonyl group, a heterocyclic group, and an oxo group.

Preferable examples of the optionally substituted benzene ring include a benzene ring which may optionally be substituted by 1-3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyldienemethyl group, a cycloalkenyl group, a cycloalkyloxy group, an aryl group, an arylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an
alkanoylamino group, an alkoxy carbonylamino group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkyl carbamoyl group, an alkanoyl group, an alkylsulfonlamino group, an arylsulfonlamino group, an alkylsulfinyl group, an alkylsulfonyl group, an arylsulfonyl group, a heterocyclic group, an alkyne group, an alkyleneoxy group, an alkylenedioxy group, and an alkenylene group.

In another preferable embodiment of the present invention, the optionally substituted unsaturated monocyclic heterocyclic ring is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkylnyl group, a cycloalkyl group, a cycloalkyldiene methyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonamino group, an alkylsulfanyl group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxy carbonylamino group, a sulfamoyl group, a mono- or di-alkyl sulfamoyl group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkyl carbamoyl group, an alkylsulfonylamino group, a phenyl group, a phenoxy group, a phenylsulfonlamino group, a phenylsulfonamino group, a heterocyclic group, and an oxo group;

the optionally substituted unsaturated fused heterobicyclic ring is an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkylnyl group, a cycloalkyl group, a cycloalkyldiene methyl group, an alkoxy group, an alkylnyl group, an alkylthio group, an alkylsulfonamino group, an alkylsulfanyl group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxy carbonylamino group, a sulfamoyl group, a mono- or di-alkyl sulfamoyl group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkyl carbamoyl group, an alkanoyl group, an alkylsulfonlamino group, a phenyl group, a phenoxy group, a phenylsulfonlamino group, phenylsulfonamino group, a heterocyclic group, and an oxo group; and

the optionally substituted benzene ring is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the
group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro
group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a
cycloalkylidenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio
group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or
di-alkylamino group, an alkanoylamino group, an alkoxy carbonylamino group, a
sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an
alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group,
an alkylsufonylamino group, a phenyl group, a phenoxy group, a phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclyl group, an
alkylene group, and an alkenylene group;
wherein each of the above-mentioned substituents on the unsaturated
monocyclic heterocyclic ring, the unsaturated fused heterobicyclic ring and the
benzene ring may further be substituted by 1-3 substituents, independently
selected from the group consisting of a halogen atom, a hydroxy group, a
cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy
group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, a mono- or
di-alkylamino group, a carboxyl group, an alkoxy carbonyl group, a phenyl
group, an alkyleneoxy group, an alkylenedioxy group, an oxo group, a
carbamoyl group, and a mono- or di-alkylcarbamoyl group.

In a preferable embodiment, the optionally substituted unsaturated
monocyclic heterocyclic ring is an unsaturated monocyclic heterocyclic ring
which may optionally be substituted by 1-3 substituents, independently selected
from the group consisting of a halogen atom, a cyano group, an alkyl group, an
alkoxy group, an alkanoyl group, a mono- or di-alkylamino group, an
alkanoylamino group, an alkoxy carbonylamino group, a carboxyl group, an
alkoxycarbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group,
a phenyl group, a heterocyclyl group, and an oxo group;
the optionally substituted unsaturated fused heterobicyclic ring is an
unsaturated fused heterobicyclic ring which may optionally be substituted by 1-
3 substituents independently selected from the group consisting of a halogen
atom, a cyano group, an alkyl group, an alkoxy group, an alkanoyl group, a
mono- or di-alkylamino group, an alkanoylamino group, an
alkoxycarbonylamino group, a carboxy group, an alkoxy carbonyl group, a
carbamoyl group, a mono- or di-alkylcarbamoyl group, a phenyl group, a heterocyclyl group, and an oxo group; and

the optionally substituted benzene ring is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, an alkoxy group, an alkanoyl group, a mono- or di-alkylamino group, an alkanoylamino group, an alkoxy carbonylamino group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkyl carbamoyl group, a phenyl group, a heterocyclyl group, an alkylenegroup, and an alkenylene group;

wherein each of the above-mentioned substituents on the unsaturated monocyclic heterocyclic ring, the unsaturated fused heterobicyclic ring and the benzene ring may further be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkanoyl group, a mono- or di-alkylamino group, a carboxyl group, a hydroxy group, a phenyl group, an alkylenedioxy group, an alkyleneoxy group, an alkoxy carbonyl group, a carbamoyl group and a mono- or di-alkyl carbamoyl group.

In another preferable embodiment,

(1) Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyldienemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkyl carbamoyl group, an alkylsulfonlamino group, a phenyl group, a phenoxy group, a phenylsulfonlamino group, a phenylsulfonyl group, a heterocyclyl group, and an oxo group, and

Ring B is an unsaturated monocyclic heterocyclic ring, an unsaturated fused heterobicyclic ring, or a benzene ring, each of which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an
alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyldenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonfyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsulfonylamino group, a phenyl group, a phenoxy group, a phenylsulfonlamino group, a phenylsulfonyl group, a heterocyclyl group, an alkylene group, and an alkenylene group;

(2) Ring A is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyldenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonfyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, an alkanoylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsulfonlamino group, a phenyl group, a phenoxy group, a phenylsulfonlamino group, a phenylsulfonyl group, a heterocyclyl group, an alkylene group, and an alkenylene group, and

Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyldenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio group, an alkylsulfonfyl group, an alkylsulfinyl group, an amino group, a mono- or di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylsulfonlamino group, a phenyl group, a phenoxy group, a phenylsulfonlamino group, a phenylsulfonyl group, a heterocyclyl group, an alkylene group and an oxo group; or

(3) Ring A is an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the
group consisting of a halogen atom, a hydroxy group, a cyano group, a nitro
group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a
cycloalkylenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio
group, an alkylsulfonyl group, an alkylsulfanyl group, an amino group, a mono- or
di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a
carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-
aldehydecarbamoyl group, an alkylsulfonylamino group, a phenyl group, a phenoxy
group, a phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclic
ring, and an oxo group, and

Ring B is an unsaturated monocyclic heterocyclic ring, an unsaturated
fused heterobicyclic ring, or a benzene ring, each of which may optionally be
substituted by 1-3 substituents, independently selected from the group
consisting of a halogen atom, a hydroxy group, a cyano group, a nitro group, an
alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a
cycloalkylenemethyl group, an alkoxy group, an alkanoyl group, an alkylthio
group, an alkylsulfonyl group, an alkylsulfanyl group, an amino group, a mono- or
di-alkylamino group, a sulfamoyl group, a mono- or di-alkylsulfamoyl group, a
carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-
aldehydecarbamoyl group, an alkylsulfonylamino group, a phenyl group, a phenoxy
group, a phenylsulfonylamino group, a phenylsulfonyl group, a heterocyclic
ring, an alkylene group and an oxo group;

wherein each of the above-mentioned substituents on Ring A and Ring
B may optionally be substituted by 1-3 substituents, independently selected
from the group consisting of a halogen atom, a cyano group, an alkyl group, a
haloalkyl group, an alkoxy group, a haloalkoxy group, an alkanoyl group, a
mono- or di-alkylamino group, a carboxyl group, a hydroxy group, a phenyl
group, an alkylenedioxy group, an alkyleneoxy group, an alkoxy carbonyl group,
a carbamoyl group and a mono- or di-alkylcarbamoyl group.

In a more preferable embodiment of the present invention, Ring A and

Ring B are

(1) Ring A is an unsaturated monocyclic heterocyclic ring which may
optionally be substituted by a halogen atom, a lower alkyl group, a halo-lower
alkyl group, a lower alkoxy group, or an oxo group, and Ring B is (a) a benzene
ring which may optionally be substituted by a halogen atom; a cyano group; a lower alkyl group; a halo-lower alkyl group; a lower alkoxy group; a halo-lower alkoxy group; a mono- or di-lower alkylamino group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; (b) an unsaturated monocyclic heterocyclic ring which may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or (c) an unsaturated fused heterobicyclic ring which may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group;

(2) Ring A is a benzene ring which may optionally be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a phenyl group, or a lower alkenylene group, and Ring B is (a) an unsaturated monocyclic heterocyclic ring which may optionally be substituted by a halogen atom; a cyano group; a lower alkyl group; a halo-lower alkyl group; a phenyl-lower alkyl group; a lower alkoxy group; a halo-lower alkoxy group; a mono- or di-lower alkylamino group; a phenyl group optionally

31
substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a mono- or di-lower alkylamino group, or a carbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a mono- or di-lower alkylamino group or a carbamoyl group; (b) an unsaturated fused heterobicyclic ring which may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a phenyl-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mo- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or

(3) Ring A is an unsaturated fused heterobicyclic ring which may optionally be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or an oxo group, and Ring B is (a) a benzene ring which may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mo- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; (b) an unsaturated monocyclic heterocyclic ring which may optionally be substituted by a halogen atom; a cyano group; a lower alkyl group; a halo-lower alkyl group; a lower alkoxy group; a halo-lower alkoxy group; a mono- or di-lower alkylamino group; a phenyl group optionally substituted by a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a
lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; or (c) an unsaturated fused heterobicyclic ring which may optionally be substituted by a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mo- or di-lower alkylamino group, a phenyl group which may be substituted with a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group; and a heterocyclyl group which may optionally be substituted with a group selected from a halogen atom, cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a mono- or di-lower alkylamino group.

In another more preferable embodiment, Y is -CH₂- and is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A is a benzene ring which is substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, a phenyl group, and a lower alkenylene group, and Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halo-lower alkyl group, a phenyl-lower alkyl group, a halogen atom, a lower alkoxy group, a halo-lower alkoxy group, a phenyl group, a halophenyl group, a cyanophenyl group, a lower alkylphenyl group, a halo-lower alkylphenyl group, a lower alkoxyphenyl group, a halo-lower alkoxy phenyl group, a lower alkylenedioxyphenyl group, a lower alkyleneoxy phenyl group, a mono- or di-lower alkylaminophenyl group, a carbamoyl phenyl group, a mono- or di-lower alkylcarbamoylphenyl group, a heterocyclyl group, a haloheterocyclyl group, a cyano heterocyclyl group, a lower alkylheterocyclyl group, a lower alkoxyheterocyclyl group, a mono- or di-lower alkylaminoheterocyclyl group, a carbamoyl heterocyclyl group, and a mono- or di-lower alkylcarbamoyl group.

In another more preferable embodiment, Y is -CH₂- and is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A is an unsaturated monocyclic heterocyclic ring which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a
halogen atom, a lower alkoxy group, and an oxo group, and Ring B is a benzene ring which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, a halo-lower alkoxy group, a phenyl group, a halophenyl group, a cyanophenyl group, a lower alkylphenyl group, a halo-lower alkylphenyl group, a lower alkoxyphenyl group, a heterocyclic group, a haloheterocyclic group, a cyano-heterocyclic group, a lower alkylheterocyclic group, and a lower alkoxyheterocyclic group.

Further, in another preferable embodiment, Y is -CH$_{2}$- and is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A is an unsaturated monocyclic heterocyclic ring which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halogen atom, a lower alkoxy group, and an oxo group, and Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may be substituted by 1-3 substituents selected from the group consisting of a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, a halo-lower alkoxy group, a phenyl group, a halophenyl group, a cyanophenyl group, a halo-lower alkylphenyl group, a lower alkoxyphenyl group, a halo-lower alkoxyphenyl group, a heterocyclic group, a haloheterocyclic group, a cyano-heterocyclic group, a lower alkylheterocyclic group, and a lower alkoxyheterocyclic group.

In a more preferable embodiment of the present invention, X is a carbon atom and Y is -CH$_{2}$-.

Further, in another preferable embodiment, Ring A and Ring B are:

(1) Ring A is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a halogen atom or a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, a phenyl group, and a lower alkenylene group, and

Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen
atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a carbamoyl group; a heterocycl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group or a carbamoyl group; and an oxo group,

(2) Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group, and

Ring B is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; a lower alkylene group,

(3) Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a halogen atom or a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group,

Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may optionally be substituted by 1-3
substituents, independently selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; a heterocyclic group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; and an oxo group;

(4) Ring A is an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group,

Ring B is a benzene ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; a heterocyclic group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; and a lower alkylene group, or

(5) Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group,

Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring, each of which may optionally be substituted by 1-3
substituents, independently selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group or a phenyl group; a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group; a cycloalkyl group; a cycloalkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; and an oxo group.

In another preferable embodiment of the present invention, Y is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A is a benzene ring which may optionally be substituted by a halogen atom, a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group, or a phenyl group, and Ring B is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom or a phenyl group; a lower alkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a lower alkoxy group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group; an oxo group.

In another more preferable embodiment of the present invention, Y is linked at the 3-position of Ring A, with respect to X being the 1-position, Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by a substituent selected from a halogen atom, a lower alkyl group, and an oxo group, and Ring B is a benzene ring which may optionally be substituted by a substituent selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted by a halogen atom or a phenyl group; a lower alkoxy group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group; and an oxo group.
cyano group, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group; and a lower alkylene group.

Preferable examples of unsaturated monocyclic heterocyclic ring include a 5- or 6-membered unsaturated heterocyclic ring containing 1 or 2 hetero atoms independently selected from a nitrogen atom, an oxygen atom, and a sulfur atom. More specifically, preferred are furan, thiophene, oxazole, isoxazole, triazole, tetrazole, pyrazole, pyridine, pyrimidine, pyrazine, dihydroisoxazole, dihydropyridine, and thiazole. Preferable unsaturated fused heterobicyclic ring includes a 9- or 10-membered unsaturated fused heterocyclic ring containing 1 to 4 hetero atoms independently selected from a nitrogen atom, an oxygen atom, and a sulfur atom. More specifically, preferred are indoline, isoindoline, benzothiazole, benzoazole, indole, indazole, quinoline, isoquinoline, benzo thiophene, benzofuran, thienothiophene, and dihydroiso quinoline.

In a more preferred embodiment of the present invention, Ring A is a benzene ring which may optionally be substituted by a substituent selected from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a phenyl group, and Ring B is a heterocyclic ring selected from the group consisting of thiophene, furan, benzofuran, benzo thiophene, and benzothiazole, wherein the heterocyclic ring may optionally be substituted by a substituent selected from the following group: a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a phenyl-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a phenyl group, a halophenyl group, a lower alkylphenyl group, a lower alkoxyphenyl group, a thienyl group, a halothienyl group, a pyridyl group, a halopyridyl group, and a thiazolyl group.

In yet another preferred embodiment, Y is -CH$_2$-, Ring A is an unsaturated monocyclic heterocyclic ring or an unsaturated fused heterobicyclic ring selected from the group consisting of thiophene, dihydroisoquinoline, dihydroisoxazole, triazole, pyrazole, dihydropyridine, dihydroindole, indole, indazole, pyridine, pyrimidine, pyrazine, quinoline, and iso indoline, wherein the heterocyclic ring may optionally substituted by a substituent selected from the following group: a halogen atom, a lower alkyl group, and an oxo group,
and Ring B is a benzene ring which may optionally be substituted by a substituent selected from the following group: a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a halo-lower alkoxy group.

In a further preferred embodiment of the present invention, Ring A is a benzene ring which is substituted by a halogen atom or a lower alkyl group, and Ring B is thieryl group which is substituted by phenyl group or a heterocycl group in which said phenyl group and heterocycl group is substituted by 1-3 substituents selected from a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a halo-lower alkoxy group.

Further, in another aspect of the present invention, preferable examples of the compound of the formula I include a compound wherein Ring A is

![Chemical Structure](image)

wherein $R^{1a}$, $R^{2a}$, $R^{3a}$, $R^{1b}$, $R^{2b}$, and $R^{3b}$ are each independently a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkyloxy group, a phenyl group, a phenylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alklamino group, an alkanoylamino group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alky carbamoyl group, an alkanoyl group, an alkylsulfonylamino group, a phenylsulfonylamino group, an alkylsulfanyl group, an alkylsulfonyl group, or a phenylsulfonyl group, and

Ring B is

![Chemical Structure](image)
wherein \( R^{4a} \) and \( R^{5a} \) are each independently a hydrogen atom; a halogen atom; a hydroxy group; an alkoxy group; an alkyl group; a haloalkyl group; a haloalkoxy group; a hydroxyalkyl group; an alkoxyalkyl group; a phenylalkyl group; an alkoxyalkoxy group; a hydroxyalkoxy group; an alkenyl group; an alkynyl group; a cycloalkyl group; a cycloalkylidenemethyl group; a cycloalkenyl group; a cycloalkyloxy group; a phenyloxy group; a phenylalkoxy group; a cyano group; a nitro group; an amino group; a mono- or di-alkylamino group; an alkanoylamino group; a carboxyl group; an alkoxy carbonyl group; a carbamoyl group; a mono- or di-alkylcarbamoyl group; an alkanoyl group; an alkylsulfonylamino group; a phenylsulfonylamino group; an alkylsulfanyl group; an alkylsulfonyl group; a phenylsulfonyl group; a phenylsulfanyl group; a phenyl group optionally substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkyl enedioxy group, an alkyleneoxy group, a mono- or di-alkylamino group, a carbamoyl group, or a mono- or di-alkylcarbamoyl group; or a heterocycyl group optionally substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a carbamoyl group, or a mono- or di-alkylcarbamoyl group, or \( R^{4a} \) and \( R^{5a} \) are bonded to each other at the terminals thereof to form an alkylene group; and

\( R^{4b}, R^{5b}, R^{4c} \) and \( R^{5c} \) are each independently a hydrogen atom; a halogen atom; a hydroxy group; an alkoxy group; an alkyl group; a haloalkyl group; a haloalkoxy group; a hydroxyalkyl group; an alkoxyalkyl group; a phenylalkyl group; an alkoxyalkoxy group; a hydroxyalkoxy group; an alkenyl group; an alkynyl group; a cycloalkyl group; a cycloalkylidenemethyl group; a cycloalkenyl group; a cycloalkyloxy group; a phenyloxy group; a phenylalkoxy group; a cyano group; a nitro group; an amino group; a mono- or di-alkylamino group; an alkanoylamino group; a carboxyl group; an alkoxy carbonyl group; a carbamoyl group; a mono- or di-alkylcarbamoyl group; an alkanoyl group; an alkylsulfonylamino group; a phenylsulfonylamino group; an alkylsulfanyl group; an alkylsulfonyl group; a phenylsulfanyl group; a phenylsulfonyl group; a phenyl group optionally substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a methylenedioxy group, an ethyleneoxy group, or a mono- or di-alkylamino group; or a heterocycyl group
optionally substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group or a haloalkoxy group.

More preferred is a compound wherein R\textsuperscript{1a}, R\textsuperscript{2a}, R\textsuperscript{3a}, R\textsuperscript{1b}, R\textsuperscript{2b}, and R\textsuperscript{3b} are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a phenyl group;

R\textsuperscript{4a} and R\textsuperscript{5a} are each independently a hydrogen atom; a halogen atom; a lower alkyl group; a halo-lower alkyl group; a phenyl-lower alkyl group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group, or R\textsuperscript{4a} and R\textsuperscript{5a} are bonded to each other at the terminals thereof to form a lower alkylene group; and

R\textsuperscript{4b}, R\textsuperscript{5b}, R\textsuperscript{4c} and R\textsuperscript{5c} are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group.

Further preferred is a compound in which Ring B is

\[
\begin{array}{c}
\text{S} \\
\text{R}^4 \\
\text{R}^5
\end{array}
\]

wherein R\textsuperscript{4a} is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylendioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group, and

R\textsuperscript{5a} is a hydrogen atom, or

R\textsuperscript{4a} and R\textsuperscript{5a} are bonded to each other at the terminals thereof to form a lower alkylene group.

Further more preferred is a compound in which Ring A is
wherein \( R^{1a} \) is a halogen atom, a lower alkyl group, or a lower alkoxy group, and \( R^{2a} \) and \( R^{3a} \) are hydrogen atoms; and Ring B is

![Diagram]

wherein \( R^{4a} \) is a phenyl group optionally substituted by a substituent selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group, and \( R^{5a} \) is a hydrogen atom, and \( Y \) is \( -\text{CH}_2^- \).

In more preferable embodiment, \( R^{4a} \) is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group.

In another preferable embodiment of the present invention, a preferable compound can be represented by the following formula IA:

![Diagram]

wherein \( R^A \) is a halogen atom, a lower alkyl group or a lower alkoxy group; \( R^B \) is a phenyl group optionally substituted by 1-3 substituents selected from a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a lower halo-lower alkoxy group; \( R^C \) is a lower alkoxy group; and \( Y \) is \( -\text{CH}_2^- \).
group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by 1-3 substituents selected from a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; and R^c is hydrogen atom; or R^B and R^c taken together are a fused benzene ring which may be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group.

In a preferable embodiment, R^A is a halogen atom or a lower alkyl group, R^c is hydrogen atom, and R^B is phenyl group substituted by 1-3 substituents selected from a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group substituted by 1-3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group. The chemical structure of such compounds are represented by the following formula (IA'):

![Chemical Structure](IA')

wherein R^A is a halogen atom, or a lower alkyl group, Ring C is a phenyl group substituted by 1-3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an
ethyleneoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group substituted by 1-3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group.

In a more preferable embodiment, Ring C is a phenyl group substituted by 1-3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, and a mono- or di-lower alkylamino group; or a heterocyclyl group substituted by a substituent selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a halo-lower alkoxy group.

Among them, a compound in which Ring C is a phenyl group substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; or a heterocyclyl group substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group is preferred.

A preferred heterocyclyl group includes a 5- or 6-membered heterocyclyl group containing 1 or 2 hetero atoms independently selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom, or a 9- or 10-membered heterocyclyl group containing 1 to 4 hetero atoms independently selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom. Specifically, a thienyl group, a pyridyl group, a pyrimidyl group, a pyrazinyl group, pyrazolyl group, a thiazolyl group, a quinolyl group, a tetrazolyl group and an oxazolyl group are preferred.

In a further preferable embodiment, Ring C is a phenyl group substituted by a halogen atom or a cyano group, or a pyridyl group substituted by a halogen atom.

In another preferable embodiment of the present invention, preferred is a compound in which Ring A is
wherein $R^{1a}$ is a halogen atom, a lower alkyl group, or a lower alkoxy group, and $R^{2a}$ and $R^{3a}$ are hydrogen atoms; and Ring B is

![Diagram]

wherein $R^{4b}$ and $R^{5b}$ are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group.

In another aspect of the present invention, preferable examples of the compound I include a compound represented by the following formula IB:

![Diagram]

wherein $R^8$, $R^9$ and $R^{10}$ are each independently a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxyalkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkyloxy group, an aryloxy group, an arylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an alkylcarbonylamino group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkyl carbamoyl group, an alkanoyl group, an alkylsulfonylamino group, an arylsulfonylamino group, an alkylsulfinyl group, an alkylsulfonyl group, or an ary lsulfonyl group; and

a group represented by:
wherein $R_6^a$ and $R_7^a$ are each independently a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an alkyl group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxyalkoxy group, an alkyl group, an alkynyl group, a cycloalkyl group, a cycloalkylidenemethyl group, a cycloalkenyl group, a cycloalkyloxy group, an aryloxy group, an arylalkoxy group, a cyano group, a nitro group, an amino group, a mono- or di-alkylamino group, an alkylcarbonylamino group, a carboxyl group, an alkoxy carbonyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkanoyl group, an alkylsulfonlamino group, an arylsulfonlamino group, an alkylsulfiny group, an alkylsulfonyl group, or an arylsulfonlamino group and $R_6^b$ and $R_7^b$ are each independently a hydrogen atom, a halogen atom, an alkyl group, a haloalkyl group, or an alkoxy group.

Among the compounds represented by the formula IB, more preferred is a compound in which $R_8$, $R_9$ and $R_{10}$ are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a cycloalkyl group, a hydroxy-lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a cycloalkoxy group, a lower hydroxy-lower alkyl group, or a lower alkoxy group, and

a group represented by:

```
\[
\begin{array}{c}
\text{R}_6^a \\
\text{R}_7^a \\
\text{R}_8
\end{array}
\]
```
wherein $R^6$, $R^7$ are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a cycloalkyl group, a hydroxy-lower alkyl group, a halo-lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkoxy group, a cycloalkoxy group, a halo-lower alkoxy group, or a lower alkoxy-lower alkoxy group, or a group represented by:

10 wherein $R^6b$ and $R^7b$ are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, or a lower alkoxy group.

In another aspect of the present invention, preferable examples of the compound I include a compound represented by the following formula IC:

wherein Ring $B'$ is an optionally substituted benzene ring, an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring.
Preferable examples of Ring B’ include a benzene ring and a heterocyclic ring, both of which may have a substituent(s) selected from the group consisting of a halogen atom; a cyano group; a lower alkyl group optionally substituted by a halogen atom; a lower alkoxy group optionally substituted by a halogen atom; a lower alkanoyl group; a mono- or di-lower alkilamino group; a lower alkoxy carbonyl group; a carbamoyl group; a mono- or di-lower alkyl carbamoyl group; a phenyl group optionally substituted by a substituent(s) selected from a halogen atom, a cyano group, a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group optionally substituted by a halogen atom, a lower alkanoyl group, a mono- or di-lower alkilamino group, a lower alkoxy carbonyl group, a carbamoyl group, or a heterocyclyl group optionally substituted by a substituent(s) selected from a halogen atom, a cyano group, a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group optionally substituted by a halogen atom, a lower alkanoyl group, a mono- or di-lower alkilamino group, a lower alkoxy carbonyl group, a carbamoyl group, or a mono- or di-lower alkyl carbamoyl group; an alkylene group; and an oxo group.

More preferable examples of Ring B’ include a benzene ring which may be substituted by a substituent selected from the group consisting of a halogen atom; a cyano group; a lower alkyl group optionally substituted by a halogen atom; a lower alkoxy group optionally substituted by a halogen atom; a mono- or di-lower alkilamino group; a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group optionally substituted by a halogen atom; a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group optionally substituted by a halogen atom, a lower alkoxy group optionally substituted by a halogen atom.

Preferred compound of the present invention may be selected from the following group:

\[ \text{1-}^\beta\text{-D-glucopyranosylH-chloro-S}^\wedge \text{-ethylbenzothiophen}^\wedge\text{-ylmethyl)benzene;} \]
1-(β-D-glucopyranosyl)-4-chloro-3-[5-(5-thiazolyl)-2-thienylmethyl]benzene;
1-(β-D-glucopyranosyl)-4-chloro-3-(5-phenyl-2-thienylmethyl)benzene;
1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene;
1-(β-D-glucopyranosyl)-4-chloro-3-[5-(2-pyrimidinyl)-2-thienylmethyl]benzene;
1-(β-D-glucopyranosyl)-4-methyl-3-[5-(2-pyrimidinyl)-2-thienylmethyl]benzene;
1-(β-D-glucopyranosyl)-4-chloro-3-[5-(3-cyanophenyl)-2-thienylmethyl]benzene;
1-(β-D-glucopyranosyl)-4-chloro-3-[5-(4-cyanophenyl)-2-thienylmethyl]benzene;
1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluoro-3-pyridyl)-2-thienylmethyl]benzene;
1-(β-D-glucopyranosyl)-4-fluoro-3-(5-(3-cyanophenyl)-2-thienylmethyl)benzene;

the pharmaceutically acceptable salt thereof; and the prodrug thereof.
Particularly preferred compounds of the present invention include:

1-(β-D-glucopyranosyl)-4-methyl-3-[5-(3-cyano-phenyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;
1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-cyano-phenyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluoro-phenyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

1-(β-D-glucopyranosyl)-4-chloro-3-[5-(3-cyano-phenyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-2-pyridyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof;

1-(β-D-glucopyranosyl)-4-fluoro-3-(5-(3-cyanophenyl)-2-thienylmethyl)benzene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Abbreviations used in the specification, particularly the Schemes and Examples, are as follows:

- BF$_3$OEt$_2$ = Boron Trifluoride Diethyl Etherate
- DCE = Dichloroethane
- DCM = Dichloromethane
- DMAP = 4-(N,N-Dimethylamino)pyridine
- DMF = N,N-Dimethylformamide
- Et$_3$SiH = Triethyl Silane
- IPA = Isopropyl Alcohol
- MeOH = Methanol
- MTBE = Methyl-t-butyl Ether
NMM = N-methyl-morpholine
TEA = Triethylamine
THF = Tetrahydrofuran

In general, for commercial use it is preferred that a product exhibit good handling qualities. Additionally, for commercial use, it is preferred that the product is produced in a substantially pure and crystalline form, to enable formulations to meet exacting pharmaceutical requirements and specifications. Further, for commercial scale preparation, it is preferred that the product be in a form that is readily filterable and easily dried. Finally, it is preferred that the product be stable for extended periods of time without the need for specialized storage conditions.

As used herein, unless otherwise noted, the term "isolated form" shall mean that the compound is present in a form which is separate from any solid mixture with another compound(s), solvent system or biological environment.

In an embodiment, the compound of formula (I), the compound of formula (I-S), the compound of formula (I-K), the crystalline form of the compound of formula (I-S) and / or the crystalline form of the compound of formula (I-K) is present and / or prepared in an isolated form.

As used herein, unless otherwise noted, the term "substantially pure" shall mean that the mole percent of impurities in the isolated compound is less than about 5 mole percent, preferably less than about 2 mole percent, more preferably, less than about 0.5 mole percent, most preferably, less than about 0.1 mole percent. In an embodiment, the compound of formula (I), the compound of formula (I-S), the compound of formula (I-K), the crystalline form of the compound of formula (I-S) and / or the crystalline form of the compound of formula (I-K) is present and / or prepared in substantially pure form.

As used herein, unless otherwise noted, the term "substantially free of a corresponding salt form(s)" when used to described the compound of formula (I) shall mean that mole percent of the corresponding salt form(s) in the isolated base of formula (I) is less than about 5 mole percent, preferably less than about 2 mole percent, more preferably, less than about 0.5 mole percent, most preferably less than about 0.1 mole percent. In an embodiment, the
compound of formula (I), the compound of formula (I-S), the compound of formula (I-K), the crystalline form of the compound of formula (I-S) and/or the crystalline form of the compound of formula (I-K) is present and/or prepared in a form which is substantially free of corresponding salt forms.

In an embodiment, the present invention is directed to a process for the preparation of a compound of formula (I), wherein the compound of formula (I) is substantially pure. In another embodiment, the present invention is directed to a process for the preparation of a compound of formula (I-S), wherein the compound of formula (I-S) is substantially pure. In another embodiment, the present invention is directed to a process for the preparation of a compound of formula (I-K), wherein the compound of formula (I-K) is substantially pure.

In an embodiment, the present invention is directed to a process for the preparation of a compound of formula (I), wherein the compound of formula (I) is substantially free of corresponding salt forms. In another embodiment, the present invention is directed to a process for the preparation of a compound of formula (I-S), wherein the compound of formula (I-S) is substantially free of corresponding salt forms. In another embodiment, the present invention is directed to a process for the preparation of a compound of formula (I-K), wherein the compound of formula (I-K) is substantially free of corresponding salt forms.

The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. Preferably, the subject has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or prevented.

The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well
as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

The compound of formula (I) of the present invention exhibits an excellent inhibitory activity against sodium-dependent glucose transporter, and an excellent blood glucose lowering effect. Therefore, the compound of the present invention is useful for treating or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension. In particular, the compound of the present invention is useful in the treatment or the prophylaxis of diabetes mellitus (type 1 and type 2 diabetes mellitus, etc.), diabetic complications (such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy) or obesity, or is useful in the treatment of postprandial hyperglycemia.

The compound of formula (I) of the present invention or a pharmaceutically acceptable salt thereof may be administered either orally or parenterally, and can be used in the form of a suitable pharmaceutical preparation. Suitable pharmaceutical preparation for oral administration includes, for example, solid preparation such as tablets, granules, capsules, powders, etc., or solution preparations, suspension preparations, or emulsion preparations, etc. Suitable pharmaceutical preparation for parenteral administration includes, for example, suppositories; injection preparations and intravenous drip preparations using distilled water for injection, physiological saline solution or aqueous glucose solution; or inhalant preparations.

The dosage of the present compound of formula (I) or a pharmaceutically acceptable salt thereof may vary according to the administration routes, ages, body weight, conditions of a patient, or kinds and severity of a disease to be treated, and it is usually in the range of about 0.01 to 300 mg/kg/day, or any range therein, preferably in the range of about 0.1 to 50 mg/kg/day, or any range therein, preferably in the range of about 0.1 to 30 mg/kg/day, or any range therein.
The compound of the formula I may be used, if necessary, in combination with one or more of other antidiabetic agents, one or more agents for treating diabetic complications, and/or one or more agents for treatment of other diseases. The present compound and these other agents may be administered in the same dosage form, or in a separate oral dosage form or by injection.

The other antidiabetic agents include, for example, antidiabetic or antihyperglycemic agents including insulin, insulin secretagogues, or insulin sensitizers, or other antidiabetic agents having an action mechanism different from SGLT inhibition, and 1, 2, 3 or 4 of these other antidiabetic agents may preferably be used. Concrete examples thereof are biguanide compounds, sulfonylurea compounds, α-glucosidase inhibitors, PPARγ agonists (e.g., thiazolidinedione compounds), PPARα/γ dual agonists, dipeptidyl peptidase IV (DPP4) inhibitors, mitiglinide compounds, and/or nateglinide compounds, and insulin, glucagon-like peptide-1 (GLP-1), PTP1B inhibitors, glycogen phosphorylase inhibitors, RXR modulators, and/or glucose 6-phosphatase inhibitors.

The agents for treatment of other diseases include, for example, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an anti-atherosclerotic agent and/or a hypolipidemic agent.

The SGLT inhibitors of the formula I may be used in combination with agents for treatment of diabetic complications, if necessary. These agents include, for example, PKC inhibitors and/or ACE inhibitors.

The dosage of those agents may vary according to ages, body weight, and conditions of patients, and administration routes, dosage forms, etc.

These pharmaceutical compositions may be orally administered to mammalian species including human beings, apes, dogs, etc., for example, in the dosage form of tablet, capsule, granule or powder, or parenterally administered in the form of injection preparation, or intranasally, or in the form of transdermal patch.
One skilled in the art will recognize that, where not otherwise specified, the reaction step(s) is performed under suitable conditions, according to known methods, to provide the desired product.

Examples of suitable solvents, bases, reaction temperatures, and other reaction parameters and components are provided in the detailed descriptions which follows herein. One skilled in the art will recognize that the listing of said examples is not intended, and should not be construed, as limiting in any way the invention set forth in the claims which follow thereafter.

One skilled in the art will further recognize that, in the specification and claims as presented herein, wherein a reagent or reagent class/type (e.g. base, solvent, etc.) is recited in more than one step of a process, the individual reagents are independently selected for each reaction step and may be the same of different from each other. For example wherein two steps of a process recite an organic or inorganic base as a reagent, the organic or inorganic base selected for the first step may be the same or different than the organic or inorganic base of the second step.

To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term "about". It is understood that whether the term "about" is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value.

To provide a more concise description, some of the quantitative expressions herein are recited as a range from about amount X to about amount Y. It is understood that wherein a range is recited, the range is not limited to the recited upper and lower bounds, but rather includes the full range from about amount X through about amount Y, or any range therein.

As used herein, unless otherwise noted, the term "nitrogen protecting group" shall mean a group which may be attached to a nitrogen atom to protect said nitrogen atom from participating in a reaction and which may be readily removed following the reaction. Suitable nitrogen protecting groups include, but are not limited to carbamates - groups of the formula -C(O)O-R
wherein R is for example methyl, ethyl, t-butyl, benzyl, phenylethyl, CH=CH-CH=CH₂, and the like; amides - groups of the formula -C(O)-R' wherein R' is for example methyl, phenyl, trifluoromethyl, and the like; N-sulfonyl derivatives - groups of the formula -SO₂-R" wherein R" is for example tolyl, phenyl, trifluoromethyl, 2,5,7,8-pentamethylchroman-6-yl-, 2,3,6-trimethyl-4-methoxybenzene, and the like. Other suitable nitrogen protecting groups may be found in texts such as T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.

One skilled in the art will recognize that wherein a reaction step of the present invention may be carried out in a variety of solvents or solvent systems, said reaction step may also be carried out in a mixture of the suitable solvents or solvent systems.

Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric salts by salt formation with an optically active acid, such as (-)-di-p-toluoyl-D-tartaric acid and/or (+)-di-p-toluoyl-L-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.

During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
One skilled in the art will recognize that in any of the processes described herein, reactive substituents on the compounds of formula (I), such as hydroxy groups, oxo groups, carboxy groups, and the like, are preferably protected and subsequently de-protected, according to known methods, at suitable points along the synthesis route.

The present invention is directed to a process for the preparation of compounds of formula (I) as outlined in Scheme 1, below.

Scheme 1

Accordingly, a suitably substituted compound of formula (V), a known compound or compound prepared by known methods, is reacted with a
compound of formula (VI-S), a known compound or compound prepared by known methods; wherein the compound of formula (VI-S) is preferably present in an amount in the range of from about 1.0 to about 2.0 molar equivalents, or any range therein, more preferably in an amount in the range of from about 1.0 to about 1.25 molar equivalents, or any range therein, most preferably about 1.2 molar equivalents;

in the presence of an alkyl lithium such as thmethylsilylmethyl lithium, mesityl lithium (i.e. 2,4,6-thmethylphenyl lithium), triethylsilylmethyl lithium, preferably trimethylsilylmethyl lithium and the like, wherein the alkyl lithium is preferably present in an amount in the range of from about 2.0 to about 3.0 molar equivalents, or any range therein, more preferably in an amount in the range of from about 2.0 to about 2.5 molar equivalents, or any range therein, most preferably about 2.0 molar equivalents;

in an organic solvent such as THF, hexane, pentane, MTBE, dioxane, and the like, preferably THF; at a temperature in the range of from about 0°C to about -78°C, or any range therein, preferably at about -40°C; to yield the corresponding compound of formula (VII).

Preferably, the alkyl lithium is added to a mixture of the compound of formula (V) and the compound of formula (VI-S).

One skilled in the art will recognize that the compound of formula (V) may alternatively be reacted (as described above) with a compound of formula (VI-S), wherein the thmethylsilyl (TMS) substituents are substituted with one or more suitably selected alternate silyl groups such as triethyldimethylsilyl, phenyltrimethylsilyl, and the like.

The compound of formula (VII) is reacted with BF$_3$OEt$_2$ in the presence of a suitably selected thalkylsilane such as Et$_3$SiH, and the like; wherein the BF$_3$OEt$_2$ is preferably present in an amount in the range of from about 2.0 to about 10.0 molar equivalents, or any range therein, more preferably, in an amount in the range of from about 2.0 to about 6.0 molar equivalents, most preferably about 3.0 molar equivalents; and wherein the trialkylsilane is preferably present in an amount in the range of from about 2.0 to about 10.0
molar equivalents, or any range therein, more preferably, in an amount in the range of from about 2.0 to about 6.0 molar equivalents, or any range therein, most preferably about 3.0 molar equivalent; preferably, wherein the ratio of the BF$_3$OEt$_2$ to the trialkylsilane is about 1:1;

in an organic solvent such as DCM, DCE, acetonitrile, toluene, and the like, or in a mixture of said organic solvents, preferably in DCM; preferably at a temperature in the range of from about 0°C to about -40°C, or any range therein, more preferably at about -30°C; to yield the corresponding compound of formula (VIII).

One skilled in the art will recognize that the compound of formula (VII) may alternatively be de-protected according to known methods (for example by reacting with a suitably selected acid such as HCl, and the like), to yield the corresponding compound of formula (X)

![Diagram of compound X]

which is then reacted with BF$_3$OEt$_2$ in the presence of a suitably selected trialkylsilane such as Et$_3$SiH, and the like; wherein the BF$_3$OEt$_2$ is preferably present in an amount in the range of from about 2.0 to about 10.0 molar equivalents, or any range therein, more preferably, in an amount in the range of from about 2.0 to about 6.0 molar equivalents, most preferably about 3.0 molar equivalents; and wherein the trialkylsilane is preferably present in an amount in the range of from about 2.0 to about 10.0 molar equivalents, or any range therein, more preferably, in an amount in the range of from about 2.0 to about 6.0 molar equivalents, or any range therein, most preferably about 3.0 molar equivalent; preferably, wherein the ratio of the BF$_3$OEt$_2$ to the trialkylsilane is about 1:1;
in an organic solvent such as DCM, DCE, acetonitrile, toluene, and the like, or in a mixture of said organic solvents, preferably in DCM; preferably at a temperature in the range of from about 0°C to about -40°C, or any range therein, more preferably at about -30°C; to yield the corresponding compound of formula (VIII).

The compound of formula (VIII) is reacted with acetic anhydride or acetyl chloride, preferably acetic anhydride, a known compound; wherein the acetic anhydride is preferably present in an amount in the range of from about 4.0 to about 6.0 molar equivalents, or any range therein, more preferably in an amount in the range of from about 4.5 to about 5.0 molar equivalents, or any range therein, most preferably about 5.0 molar equivalents;

in the presence of an organic base such as N-methylmorpholine (NMM), TEA, pyridine, and the like, preferably NMM; wherein the organic base is preferably present in an amount in the range of from about 3.0 to about 6.0 molar equivalents, or any range therein, more preferably about 5.0 molar equivalents; optionally in the presence of a catalyst such as DMAP, and the like; preferably in the presence of a catalytic amount of DMAP;

preferably, THF; preferably, at a temperature in the range of from about -10°C to about room temperature, or any range therein, preferably at a temperature in the range of from about 0°C to about room temperature; to yield the corresponding compound of formula (IX).

The compound of formula (IX) is preferably slurried or dissolved in a solvent, more preferably slurried; and then filtered, preferably filtered at an elevated temperature, to remove impurities and/or byproducts.

The compound of formula (IX) is de-protected according to known methods. For example, the compound of formula (IX) is reacted with a suitably selected base such as LiOH, NaOH, and the like, preferably LiOH; wherein the base is preferably present in an amount in the range of from about 0.1 to about 1.0 molar equivalent, or any range therein, more preferably from about 0.25 to about 0.5 molar equivalents, or any range therein, most preferably about 0.5
molar equivalents, (for example, a catalytic amount); in a mixture of water, THF and methanol, wherein the ratio of water : THF : methanol is preferably about 1:2:3; preferably at about room temperature; to yield the corresponding compound of formula (I).

The compound of formula (I) is preferably isolated and/or recrystallized, according to known methods.

In an embodiment, the present invention is directed to a process for the preparation of a compound of formula (I-S), as outlined in Scheme 2, below.
Accordingly, a suitably substituted compound of formula (V-S), a known compound or compound prepared by known methods, is reacted with a compound of formula (VI-S), a known compound or compound prepared by known methods; wherein the compound of formula (VI-S) is preferably present in an amount in the range of from about 1.0 to about 2.0 molar equivalents, or any range therein, more preferably in an amount in the range of from about 1.0 to about 1.25 molar equivalents, or any range therein, most preferably about 1.2 molar equivalents;

in the presence of an alkyl lithium such as thmethylsilylmethyl lithium, mesityl lithium (i.e. 2,4,6-thmethylphenyl lithium), triethylsilylmethyl lithium, preferably trimethylsilylmethyl lithium and the like, wherein the alkyl lithium is preferably present in an amount in the range of from about 2.0 to about 3.0 molar equivalents, or any range therein, more preferably in an amount in the range of from about 2.0 to about 2.5 molar equivalents, or any range therein, most preferably about 2.0 molar equivalents;

in an organic solvent such as THF, hexane, pentane, MTBE, dioxane, and the like, preferably THF; at a temperature in the range of from about 0°C to about -78°C, or any range therein, preferably at about -40°C; to yield the corresponding compound of formula (VII-S).

Preferably, the alkyl lithium is added to a mixture of the compound of formula (V-S) and the compound of formula (VI-S).

One skilled in the art will recognize that the compound of formula (V-S) may alternatively be reacted (as described above) with a compound of formula
(VI-S), wherein the trimethylsilyl (TMS) substituents are substituted with one or more suitably selected alternate silyl groups such as triethylsilyl, phenyldimethylsilyl, and the like.

The compound of formula (VII-S) is reacted with BF$_3$OEt$_2$ in the presence of a suitably selected trialkylsilane such as Et$_3$SiH, and the like; wherein the BF$_3$OEt$_2$ is preferably present in an amount in the range of from about 2.0 to about 10.0 molar equivalents, or any range therein, more preferably, in an amount in the range of from about 2.0 to about 6.0 molar equivalents, most preferably about 3.0 molar equivalents; and wherein the trialkylsilane is preferably present in an amount in the range of from about 2.0 to about 10.0 molar equivalents, or any range therein, more preferably, in an amount in the range of from about 2.0 to about 6.0 molar equivalents, or any range therein, most preferably about 3.0 molar equivalent; preferably, wherein the ratio of the BF$_3$OEt$_2$ to the trialkylsilane is about 1:1;

in an organic solvent such as DCM, DCE, acetonitrile, toluene, and the like, or in a mixture of said organic solvents, preferably in DCM; preferably at a temperature in the range of from about 0°C to about -40°C, or any range therein, more preferably at about -30°C; to yield the corresponding compound of formula (VIII-S).

The compound of formula (VIII-S) is reacted with acetic anhydride or acetyl chloride, preferably acetic anhydride, a known compound; wherein the acetic anhydride is preferably present in an amount in the range of from about 4.0 to about 6.0 molar equivalents, or any range therein, more preferably in an amount in the range of from about 4.5 to about 5.0 molar equivalents, or any range therein, most preferably about 5.0 molar equivalents;

in the presence of an organic base such as N-methylmorpholine (NMM), TEA, pyridine, and the like, preferably NMM; wherein the organic base is preferably present in an amount in the range of from about 3.0 to about 6.0 molar equivalents, or any range therein, more preferably about 5.0 molar equivalents; optionally in the presence of a catalyst such as DMAP, and the like; preferably in the presence of a catalytic amount of DMAP;
neat or in an organic solvent such as THF, acetonitrile, and the like, preferably, THF; preferably, at a temperature in the range of from about -10°C to about room temperature, or any range therein, preferably at a temperature in the range of from about 0°C to about room temperature; to yield the corresponding compound of formula (IX-S).

The compound of formula (IX-S) is preferably slurried or dissolved in a solvent, more preferably slurried; and then filtered, preferably at an elevated temperature, to remove impurities and/or byproducts. Preferably, the mixture of the compound of formula (IX-S) in an organic solvent such as methanol, ethanol and the like, preferably methanol, is slurried or dissolved, preferably slurried, and then filtered, preferably at an elevated temperature, to remove impurities and/or byproducts.

The compound of formula (IX-S) is de-protected according to known methods. For example, the compound of formula (IX-S) is reacted with a suitably selected base such as LiOH, NaOH, and the like, preferably LiOH; wherein the base is preferably present in an amount in the range of from about 0.1 to about 1.0 molar equivalent, or any range therein, more preferably from about 0.25 to about 0.5 molar equivalents, or any range therein, most preferably about 0.5 molar equivalents, (for example, a catalytic amount); in a mixture of water, THF and methanol, wherein the ratio of water : THF : methanol is preferably about 1.2 : 3; preferably at about room temperature; to yield the corresponding compound of formula (I-S).

The compound of formula (I-S) is preferably recrystallized. In an embodiment, the compound of formula (I-S) is recrystallized according to the following process:

**STEP A:** the compound of formula (I-S) is dissolved in an organic solvent such as ethyl acetate, methanol, ethanol and the like, preferably ethyl acetate; then optionally filtered;
STEP B: the mixture of STEP A is heated to a temperature in the range of from about 250°C to about 450°C, preferably to a temperature in the range of from about 30 to about 350°C; then optionally filtered;

STEP C: to the mixture prepared in STEP B is added water, preferably about 1.0 to about 2.0 molar equivalents, more preferably about 1.5 molar equivalents;

STEP D: to the mixture prepared in STEP C is slowly added heptane (to initiate precipitation - i.e. the heptane acts as an anti-solvent), preferably an amount such that the final volume : volume ratio of ethyl acetate : heptane was in the range of from about 1:1 to about 1.5:1, more preferably about 1.2:1;

to yield a precipitate of the compound of formula (I-S); which precipitate is preferably isolated by filtration and then dried according to known methods.

Preferably, in the recrystallization of the compound of formula (I-S), after addition of the heptane, the resulting mixture is seeded with the desired polymorph of the compound of formula (I-S).

The present invention is further directed to a novel crystalline form of the compound of formula (I-S). The present invention is further directed to a novel crystalline form of the compound of formula (I-K).

One skilled in the art will recognize that several methods for characterizing crystalline forms exist, and the present invention is not intended to be limited by the methods chosen or the instrumentation used in characterizing the compounds of the present invention. For example, with regard to powder x-ray diffraction patterns, the diffraction peak intensities in the experimental patterns can vary, as is known in the art, primarily due to preferred orientation (non-random orientation of the crystals) in the prepared sample. As such, the scope of the present invention must be considered in light of the variability of characterization that is appreciated by those skilled in the art.

The present invention is further directed to a crystalline form of the compound of formula (I-S)
In an embodiment, the present invention is directed to a crystalline form of the compound of formula (I-S) prepared according to the recrystallization process as herein described. In another embodiment, the present invention is directed to a crystalline form of the compound of formula (I-S), prepared according to the following recrystallization process:

**STEP A:** dissolving a compound of formula (I-S) in ethyl acetate to yield mixture A; then optionally filtering mixture A;

**STEP B:** heating mixture A to a temperature in the range of from about 30°C to about 35°C to yield mixture B; then optionally filtering mixture B;

**STEP C:** adding about 1.5 molar equivalents of water to mixture B, to yield mixture C;

**STEP D:** slowly adding heptane to mixture C to yield a crystalline form of the compound of formula (I-S);

**STEP E:** isolating the crystalline form of the compound of formula (I-S) by filtration and drying.

The present invention is further directed to a novel crystalline form of a compound of formula (I-K)
An X-ray powder diffraction spectra was measured for a representative sample of the crystalline form of the compound of formula (I-K) using a RINT-ULTIMA3, Rigaku, Tokyo, Japan powder x-ray diffractometer, using CuKα radiation and the following settings: (a) Scanning rate: 1.00 degree/minute; (b) Target: CuKα; (c) Voltage: 40 kV; (d) Current: 40 mA; (e) Scan range: from 3 to 40.0 degree; and (f) Sampling width: 0.0200 degree; as shown in Figure 2.

An X-ray powder diffraction pattern was further measured for a representative sample of the crystalline form of the compound of formula (I-K) using a Philips X’Pert Pro MPD powder X-ray diffractometer, using CuKα radiation and the following settings: (a) Scanning rate: 0.207 degree/minute; (b) Target: CuKα; (c) Voltage: 45 kV; (d) Current: 40 mA; (e) Detector: X’celerator; (f) Scan range: from 3 to 35 degree; (g) Step size: 0.01 65 degree; and (h) Time per step: 10.1 6 sec; as shown in Figure 3.

An Infra-red spectrum was measured for a representative samples of the crystalline form of the compound of formula (I-K) in mineral oil, as shown in Figure 4, and also in a K-Br pellet, as shown in Figure 5. In the infra-red spectra of the crystalline form of the compound (I-K) as shown in Figure 4 and Figure 5 which follow herein, the ordinate is the transmittance in % and the abscissa is the wavenumber in cm⁻¹.

The Fourier Transform Infra-red (FT-IR) spectrum of the crystalline form of the compound of formula (I-K) in mineral oil was recorded at a resolution of 4cm⁻¹. The IR spectrum as shown in Figure 4 represents the sum of 4 scans. The IR spectrum shows the major characteristic absorption bands at 1492,
1463, 1377, 1268, 1065 and 1023 cm\(^{-1}\), consistent with the functional groups present in the compound (I-K).

The Fourier Transform IR spectrum of the crystalline form of the compound (I-K) in a KBr pellet was recorded at a resolution of 4 cm\(^{-1}\). The IR spectrum, as shown in Figure 5, represents the sum of 64 scans. The IR spectrum shows the major characteristic absorption bands at 3431, 3321, 1493, 1269, 1065 and 1024 cm\(^{-1}\).

Thermogravimetric analysis was completed on a representative sample of the crystalline form of the compound of formula (I-K). The methodology of the thermogravimetric analysis performed was as follows: 7.35 mg of the crystalline form of the compound (I-K) was weighed and transferred in an aluminum cell holder for TG-8120 (RIGAKU, Japan). The thermogravimetric (TG) thermal curve of the crystalline form of the compound of formula (I-K) was then determined at a heat rate of 5°C/minute, with a typical measuring range from ambient temperature to 200°C. The crystalline form of the compound of formula (I-K) was not been observed in the thermogravimetric analysis to exist in a hydrate or solvate form.

The present invention is further directed to a process for the preparation of the crystalline form of the compound (I-K) which process comprises forming a solution of the compound of formula (I-K) and precipitating the crystalline form from the solution. The crystalline form of the compound of formula (I-K) may be obtained from a solution of the compound of formula (I-K) in an appropriate solvent. Sometimes some impurities may act as crystallization inhibitors, and such impurities need to be removed using a conventional manner, such as silica gel column chromatography, as would be readily recognized by one skilled in the art. However, the crystalline of the compound of formula (I-K) may be obtained from compound of formula (I-K) containing some impurities.

The crystalline form of the compound of formula (I-K) may be prepared from a solution of the compound of formula (I-K) in a suitably selected solvent. Examples of suitable solvents include, but are not limited to, ketones (e.g.,
acetone, 2-butanone), esters (e.g., ethyl acetate, methyl acetate), alcohols (e.g., methanol, ethanol, i-propanol), and a mixture of these solvents. Particularly preferred solvents include, esters such as ethyl acetate. In some cases, an anti-solvent can be added to the solution of the compound of formula (I-K). Examples of anti-solvents include alkanes (e.g., hexane, heptane), aromatic hydrocarbons (e.g., benzene, toluene), ethers (e.g., diethyl ether, dimethyl ether, diisopropyl ether) and a mixture of these solvents.

A preferred process for the preparation of the crystalline form of the compound of formula (I-K), comprises dissolving in a warmed appropriate solvent (e.g., esters) crude or amorphous compound of formula (I-K) (prepared for example in accordance with the procedures described in PCT Publication WO 2005/01 2326), and then adding an anti-solvent, as necessary, to the resulting solution, followed by cooling the resulting solution and filtration. The precise conditions under which the crystalline of the compound (I-K) is formed may be empirically determined.

One skilled in the art will recognize that the crystalline form of the compound of formula (I-K) is easier to isolate than the corresponding amorphous form of the compound of formula (I-K) and further, can be filtered from the crystallization medium after cooling, and washed and dried.

The present invention is further directed to pharmaceutical compositions comprising the crystalline form of the compound of formula (I-S) or the crystalline form of the compound of formula (I-K) and a pharmaceutically acceptable carrier.

The crystalline form of the compound of formula (I-S) and the crystalline form of the compound of formula (I-K) of the present invention are further useful as inhibitors of sodium-dependent glucose transporters (SGLT2), and show excellent blood glucose lowering effect. In an embodiment, the crystalline form of the compound of formula (I-S) and the crystalline form of the compound of formula (I-K) of the present invention are useful in the treatment, prevention or in delaying the progression or onset of diabetes mellitus (type 1 and type 2 diabetes mellitus, etc.), diabetic complications (such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy), postprandial hyperglycemia,
delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, atherosclerosis, or hypertension.

The present invention further comprises pharmaceutical compositions containing a compound prepared according to any of the processes described herein with a pharmaceutically acceptable carrier. Pharmaceutical compositions containing one or more of the compounds of the invention described herein as the active ingredient can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral). Thus for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral preparations, such as powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations may also be coated with substances such as sugars or be enteric-coated so as to modulate major site of absorption. For parenteral administration, the carrier will usually consist of sterile water and other ingredients may be added to increase solubility or preservation. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.

To prepare the pharmaceutical compositions of this invention, one or more compounds of the present invention as the active ingredient is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols,
flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, caplets, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above. The pharmaceutical compositions herein may contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.01-1000 mg or any range therein, and may be given at a dosage of from about 0.01-300 mg/kg/day, or any range therein, preferably from about 0.1-50 mg/kg/day, or any range therein. The dosages, however, may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.

Preferably these compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g.
conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.01 to about 1000 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of material can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

The methods of treating described in the present invention may also be carried out using a pharmaceutical composition comprising any of the compounds as defined herein and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain between about 0.01 mg and 1000 mg of the compound,
or any range therein; preferably about 10 to 500 mg of the compound, and may be constituted into any form suitable for the mode of administration selected. Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.

Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

The liquid forms in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methylcellulose and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
To prepare a pharmaceutical composition of the present invention, a
compound prepared according to any of the processes described herein as the
active ingredient is intimately admixed with a pharmaceutical carrier according
to conventional pharmaceutical compounding techniques, which carrier may
take a wide variety of forms depending of the form of preparation desired for
administration (e.g. oral or parenteral). Suitable pharmaceutically acceptable
carriers are well known in the art. Descriptions of some of these
pharmaceutically acceptable carriers may be found in The Handbook of
Pharmaceutical Excipients, published by the American Pharmaceutical
Association and the Pharmaceutical Society of Great Britain.

Methods of formulating pharmaceutical compositions have been
described in numerous publications such as Pharmaceutical Dosage Forms:
Lieberman et al; Pharmaceutical Dosage Forms: Parenteral Medications,
Volumes 1-2, edited by Avis et al; and Pharmaceutical Dosage Forms:
Disperse Systems, Volumes 1-2, edited by Lieberman et al; published by
Marcel Dekker, Inc.

Compounds of this invention may be administered in any of the foregoing
compositions and according to dosage regimens established in the art whenever
treatment of disorders as described herein is required.

The daily dosage may be varied over a wide range from 0.01 to 1,000 mg
per adult human per day, or any range therein. For oral administration, the
compositions are preferably provided in the form of tablets containing, 0.01, 0.05,
0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 30.0, 50.0, 75.0, 100.0, 150.0, 200.0,
250.0, 300.0 and 500 milligrams of the active ingredient for the symptomatic
adjustment of the dosage to the patient to be treated. An effective amount of the
drug is ordinarily supplied at a dosage level of from about 0.01 mg/kg to about
300 mg/kg of body weight per day, or any range therein, preferably at a dosage
level of from about 0.01 mg/kg to about 100 mg/kg, or any range therein. More
preferably, the range is from about 0.01 to about 50.0 mg/kg of body weight per
day, or any range therein, more preferably still, from about 0.01 to about 30.0
mg/kg of body weight per day, or any range therein. The compounds may be administered on a regimen of 1 to 4 times per day.

Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.

One skilled in the art will recognize that, both in vivo and in vitro trials using suitable, known and generally accepted cell and/or animal models are predictive of the ability of a test compound to treat or prevent a given disorder.

One skilled in the art will further recognize that human clinical trails including first-in-human, dose ranging and efficacy trials, in healthy patients and/or those suffering from a given disorder, may be completed according to methods well known in the clinical and medical arts.

The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims which follow thereafter.

In the Examples which follow, some synthesis products are listed as having been isolated as a residue. It will be understood by one of ordinary skill in the art that the term "residue" does not limit the physical state in which the product was isolated and may include, for example, a solid, an oil, a foam, a gum, a syrup, and the like.

**Example 1**

*(5-Bromo-2-methyl-phenyl)-r5-(4-fluoro-phenyl)-thiophen-2-vn-methanone*
STEP A:
A 250 ml three-necked round bottom flask was charged with 5-bromo-2-methylbenzoic acid (22.5 g, 0.10 mol), \( \text{CH}_2\text{Cl}_2 \) (100 ml) and DMF (0.25 ml) at ambient temperature (20°C). Oxalyl chloride (12 ml, 0.13 mol) was added such that the internal temperature was maintained below 25°C. Vigorous gas evolution was observed. The reaction mixture was stirred overnight at ambient temperature, under argon, then the volatiles were removed under reduced pressure. The resulting residue (an acid chloride compound) was dissolved in DCM (50 ml) and set aside under a nitrogen atmosphere.

STEP B:
In a separate 500 ml 3-necked round bottom flask was added AICI3 (15.0 g, 0.11 mol) and 100 ml of \( \text{CH}_2\text{Cl}_2 \). The suspension was cooled to -10°C in an ice bath then 2-(4-fluorophenyl)thiophene (18.2 g, 0.10 mol) was added followed by addition of the mixture prepared as in STEP A above. After 30 minutes the ice bath was removed and the resulting mixture stirred at ambient temperature for 2-3 h. The resulting mixture was cooled to -12°C and quenched by the slow addition of water (20 ml), followed by 2N HCl (20 ml) and heptane (100 ml). A precipitate formed. The resulting mixture was stirred for 1-2 h then filtered to give the title compound as a yellow solid.

Example 2

2-(5-Bromo-2-methyl-benzyl)-5-(4-fluoro-phenyl)-thiophene

A 3.0 L four-necked round bottom flask was charged with the compound prepared as in Example 1 above (119 g, 0.31 7 mol), triethylsilane (148 ml, 0.926 mol), dichloromethane (700 ml) and acetonitrile (700 ml). The resulting mixture was cooled to -8°C in an ice bath, with stirring, then boron trifluoride diethyl etherate (115 ml, 0.915 mol) was added dropwise, such that the temperature did not exceed 0°C. The resulting mixture was warmed to room
temperature and stirred overnight. The resulting mixture was concentrated under reduced pressure, diluted with IPA (1.0 L), filtered and washed with water to yield a solid. Recrystallization of the solid from IPA yielded the title compound as a yellow solid.

Example 3

2-(4-Fluoro-phenyl)-5-(5-iodo-2-methyl-benzyl)-thiophene

A 1.0 L four-necked reaction flask was charged with the compound prepared as in Example 2 above (100 g, 276.80 mmoles), sodium iodide (82 g, 553.59 mmoles) and Copper(I) iodide (2.6 g, 13.84 mmoles). The resulting mixture was evacuated and purged with argon, then treated with toluene (261 ml), diglyme (56 ml) and N,N'-dimethyl-ethane-1,2-diamine (2.7 ml, 27.68 mmoles) and the resulting mixture warmed to 110°C overnight. Upon consumption of starting material, the resulting mixture was cooled to room temperature, then filtered through Celite®, washed with EtOAc, and extracted with NH₄OH. The organic phase was dried (Na₂SO₄), filtered and concentrated to yield a solid. The solids were filtered and recrystallized from heptane to yield the title compound as an off white solid (m.p. 107°C).

Example 4

2,3A6-tetra-O-Trimethylsilyl- β-D-glucolactone

A 5.0 L three-necked round bottom flask was charged with gluconolactone (155.2 g, 0.871 mol) and 4-methylmorpholine (766 mL, 6.96 mol) in THF (1.55 L). To the cooled (-10°C) mixture was added chlorotrimethylsilane (660 mL, 5.21 mol) at a rate such that the temperature did not exceed 50°C. After 1 hr the reaction mixture was heated to about 35-40°C for 5 hr, then stirred at ambient temperature overnight, under argon. The resulting mixture was cooled to -10°C and water (500-600 mL) was slowly added until no severe exotherm was observed. The resulting mixture was diluted with 4.0 L of water and 2.5 L of heptane. The layers were separated and the organic phase washed with aqueous sodium phosphate monobasic (1.5 L), water (1.0 L) and brine (1.0 L). The organic layer was dried over magnesium sulfate then concentrated under vacuum to yield the title compound as a light yellow liquid.

Example 5
A 2.0 L three-necked round bottom flask was charged with the compound prepared as in Example 3 above, (100 g, 232.68 mmole), the compound prepared as in Example 4 above (141g, 302.49 mmole) and tetrahydrofuran (750 ml). Upon cooling the resulting mixture to about -40°C, 1.0 M (trimethylsilyl)methyl lithium in hexane (489 ml, 489 mmole) was charged to the mixture using an addition funnel, with the internal temperature maintained at less than or equal to about -40°C. After addition was complete, the reaction was quenched with std. NaHCO3 (200mL) and allowed to warm to room temperature. The phases were separated, dried (Na₂SO₄), filtered and concentrated to yield the title compound as a thick oil.

**Example 6**

\[ 1-(\beta-D-Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienyl)methylphenylene \]

A 2.0 L three-necked round bottom flask was charged with the compound prepared as in Example 5 above (232 g, 310 mmol) and dichloroethane (700 ml). The resulting yellow solution was cooled to -30°C in an ice bath, with stirring. The methylsilane (132 ml, 826 mmol) was added followed by a slow addition (1.75 h) of boron trifluoride diethyl etherate (95.0 ml, 756 mmol) such that the temperature did not exceed -20°C. Approximately 30 minutes after the addition was complete the ice bath was removed and the resulting yellow mixture was stirred at ambient temperature, under argon, for 1.0-1.5 hour. Upon complete reaction the resulting mixture was poured into cold water (800 ml). Ethyl acetate (300 ml) was added and the layers were separated. The organic layer was washed with a saturated bicarbonate
solution, dried over sodium sulfate and concentrated to yield the title compound as a green foam.

**Example 7**

A 2.0 L three-necked round bottom flask was charged with the compound prepared as in Example 6 above, (1.19 g, 0.25 mol), 4-methylmorpholine (145 ml, 1.30 mol), DMAP (3.25 g, 0.026 mol) and 1.0 L of THF. The resulting light green mixture was cooled to -10°C in an ice bath, with stirring, then acetic anhydride (1.25 ml, 1.30 mol) was added dropwise, such that the temperature did not exceed 0°C. The ice bath was removed 15 minutes after the addition was complete. The resulting mixture was stirred at ambient temperature for 1.0 h, then concentrated under reduced pressure at 30-35°C to remove most of the solvent. The resulting mixture was diluted with 10% phosphoric acid (~300 ml), which resulted in the formation of a cream colored precipitate. The resulting mixture was dissolved in a mix of ethyl acetate (600-800 ml), THF (200-300 ml) and toluene (200-300 ml). Once complete solution was obtained, the layers were separated and the organic layer washed with saturated bicarbonate solution and brine, then dried and concentrated to yield a thick residue. Methanol was added to the residue causing an off-white solid to precipitate out of solution. The slurry was stirred for 30 minutes, then filtered to yield the title compound as an off-white solid.
Example 8

1-(β-D-Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethylen)benzene

A flask was charged with the compound prepared as in Example 7 above, (185 g, 302 mmol) in THF (820 ml) and MeOH (1.23 L). To the stirred suspension was added a solution of lithium hydroxide monohydrate (6.33 g, 147 mmol) in water (410 ml). After stirring overnight at ambient temperature the volatiles were removed and the resulting residue diluted with ethyl acetate (500-600 ml). The layers were separated and the aqueous layer extracted with ethyl acetate (3 x 100 ml). The combined organic layer was washed with brine (250 ml), dried over sodium sulfate and concentrated under reduced pressure to yield the title compound as a brittle foam.
Example 9

Crystallization of 1-((β-D-Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene

A 1.0 L three-necked round bottom flask was charged with the compound prepared as in Example 8 above (96.9 g, 217 mmol), water (6.0 ml, 333 mmol) and ethyl acetate (275 ml). The resulting solution was heated to 35°C, with stirring, under argon. Heptane was added dropwise until the solution became hazy (155 ml heptane), followed by the addition of 14.2 g of seed crystals. After stirring for 1.5-2.0 hrs at 35°C additional heptane (30 ml, for a total of 185 ml) was added. The resulting mixture was stirred for 30 minutes more then filtered. The filter cake was washed with about 56% ethyl acetate/heptane (50 ml) and dried to yield the title compound as a fluffy, off-white crystalline solid.

The procedures as described in Examples 1 through 9 above were run multiple times to yield multiple batches of 1-((β-D-glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene, the compound of formula (I-S).

The melting point, mass spec and ¹H-NMR spectra, as measured for a representative sample of the compound of formula (I-S) (prepared according to the procedures in Example 1 through 9) are as follows:

Melting Point: 106-107°C;
Mass Spec: m/z (LCMS API-ES) 467 (M+Na);
$^1$H NMR (CD$_3$OD): δ = 2.32 (s, 3H), 3.35-3.53 (m, 4H), 3.71 (d, 1H, J = 11.9 Hz), 3.90 (d, 1H, J = 11.9 Hz), 4.13 (d, 1H, J = 9.3 Hz), 4.17 (s, 2H), 4.9 (s, 4H), 6.70 (d, 1H, J = 3.7 Hz), 7.04-7.14 (m, 3H), 7.18 (d, 1H, J = 7.8 Hz), 7.26 (d, 1H, J = 7.8 Hz), 7.33 (s, 1H), 7.52-7.60 (m, 2H).

A representative sample of the crystalline form of the compound of formula (I-S), isolated as described in Example 9 above, was characterized as to its x-ray powder diffraction, (a representative example of which is shown in Figure 1) utilizing a diffractometer using CuK$_\alpha$ radiation 30mA, 40KV; 1/12° divergence slit, 0.2 receiving slit; scanning from 4 to 35° 2θ at a scan rate of 0.01 6° 2θ/second; and using an aluminum sample holder.

The crystalline form of the compound of formula (I-S) may be characterized by its powder XRD peaks, (preferably, by its powder XRD peaks with a relative intensity of greater than about 10%, more preferably, by its powder XRD peaks with a relative intensity of greater than about 25%, more preferably still, by its powder XRD peaks with a relative intensity of greater than about 35%, more preferably still, by its powder XRD peaks with a relative intensity of greater than about 50%), as listed in Table 1 below.

<table>
<thead>
<tr>
<th>Position (2° theta)</th>
<th>d-spacing (Å)</th>
<th>Relative Intensity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.9</td>
<td>22.8</td>
<td>86.7</td>
</tr>
<tr>
<td>8.0</td>
<td>11.1</td>
<td>22.1</td>
</tr>
<tr>
<td>9.7</td>
<td>9.2</td>
<td>10.5</td>
</tr>
<tr>
<td>10.9</td>
<td>8.1</td>
<td>33.3</td>
</tr>
<tr>
<td>13.0</td>
<td>6.8</td>
<td>16.2</td>
</tr>
<tr>
<td>13.9</td>
<td>6.4</td>
<td>18.4</td>
</tr>
<tr>
<td>15.5</td>
<td>5.7</td>
<td>100</td>
</tr>
<tr>
<td>15.6</td>
<td>5.7</td>
<td>64.5</td>
</tr>
<tr>
<td>15.9</td>
<td>5.6</td>
<td>16.8</td>
</tr>
<tr>
<td>16.2</td>
<td>5.5</td>
<td>14.2</td>
</tr>
<tr>
<td>17.3</td>
<td>5.1</td>
<td>44.0</td>
</tr>
<tr>
<td>18.3</td>
<td>4.9</td>
<td>18.6</td>
</tr>
<tr>
<td>18.7</td>
<td>4.7</td>
<td>38.5</td>
</tr>
<tr>
<td>18.8</td>
<td>4.7</td>
<td>56.6</td>
</tr>
<tr>
<td>19.1</td>
<td>4.6</td>
<td>21.1</td>
</tr>
<tr>
<td>19.4</td>
<td>4.6</td>
<td>21.3</td>
</tr>
</tbody>
</table>
STEP A:

A 5.0 L four-necked round bottom flask was charged with 2-chloro-5-iodobenzoic acid (470.8 g, 1.66 mol), CH₂Cl₂ (1.6 L) and DMF (5.0 ml, 0.03 mol) at ambient temperature (20°C). Oxalyl chloride (170 ml, 1.94 mol) was added such that the internal temperature was maintained below 25°C. The addition was slightly exothermic; vigorous gas evolution occurred. The resulting mixture was stirred overnight at ambient temperature, under argon, then the volatiles were removed under reduced pressure. The resulting residue (an acid chloride compound) was diluted with dichloromethane (500 ml) and set aside under a nitrogen atmosphere.

STEP B:

In a separate 5.0 L 3-necked round bottom flask was added AlCl₃ (487.0 g, 3.65 mol) and 1.5 L of CH₂Cl₂. To the cooled (-1 2°C) mixture was added 2-fluoro-5-(2-thienyl)pyridine (299.0 g, 1.66 mol) followed by addition of the...
mixture prepared as in STEP A above. After 20 minutes the ice bath was removed and the reaction mixture stirred at ambient temperature for 2-3 h. Upon completion of the reaction the resulting mixture was cooled to -12°C and quenched by the slow addition of water (400-500 ml) followed by 2 N HCl (100 ml) and heptane (100 ml). The reaction temperature was not allowed to exceed 32°C during the water quench. The resulting mixture was stirred at ambient temperature overnight, resulting in the formation of a precipitate. The resulting mixture was filtered, washed with water and dried to yield a solid. The solid was recrystallized from ethyl acetate to yield the title compound as a gold colored solid.

Example 11
5-5-(2-Chloro-5-iodo-benzyl)-thiophen-2-vn-2-fluoro-pyridine

A 5.0 L four-necked round bottom flask was charged with the compound prepared as in Example 10 above, (350 g, 0.787 mol), triethylsilane (650 ml, 4.07 mol) and acetonithle (1.75 L). The resulting mixture was heated to 30°C then boron thfluoride diethyl etherate (500 ml, 3.98 mol) was added, dropwise, such that the temperature did not exceed 58°C. Stirring was continued at ambient temperature. Upon completion, the resulting mixture was added to a cooled (5°C) aqueous sodium bicarbonate solution (400 g in 2.0 L of water). The aqueous mixture was stirred at ambient temperature for an hour then diluted with ethyl acetate (500 ml). The layers were separated and the aqueous layer extracted with ethyl acetate (2 x 400 ml). The combined organic was washed with brine, dried and concentrated to yield a light brown solid. The solid was dissolved in hot toluene (about 1.5-1.75 L), treated with silica gel (250 g), diluted with heptane (1.0 L), stirred for 30-40 minutes then filtered hot. The volume was reduced and additional heptane added. A solid
precipitated out of solution on cooling to room temperature. The resulting mixture was filtered to yield the title compound as a yellow solid.

**Example 12**

A 1L Erlenmeyer flask was charged with the compound prepared as in Example 11 above (94.4 g, 219.70 mmoles), the compound prepared as in Example 4 above (102 g, 219.70 mmoles) and tetrahydrofuran (585 ml). The resulting mixture was filtered through a sintered glass funnel packed with Celite® and molecular sieves, 4AE (10 g) into a 2.0 L three-necked round bottom flask equipped with and overhead stirrer, nitrogen outlet, thermocouple and addition funnel with a vacuum adapter. The resulting mixture was then cooled to -70°C via dry ice / acetone bath. The addition funnel was charged with 1.0 M (trimethylsilyl)methyl lithium in hexanes (450 mL; 450 mmoles), with the internal temperature maintained at less than about -60°C. After addition was complete, the resulting mixture was allowed to warm to -30°C, then quenched into a stirred mixture of NaHCO3 (400 mL, 50% saturated) in a 2L separatory funnel, diluted with heptane (200 mL) and the phases separated. The organic phase was washed with water (200 mL), brine (50 mL) then phase separated and dried (Na2SO4), filtered and concentrated to yield the title compound as a thick oil.
A 2L three-neck round bottom flask equipped with a cold bath, addition funnel, temperature sensor, nitrogen outlet and overhead stirrer was charged with the product prepared as in Example 11 above (100 g, 232.73 mmoles) and the compound prepared as in Example 4 above (130.4 g, 325.8 mmoles), followed by addition of THF (660 mL). The resulting mixture was then cooled to -70°C via dry ice bath in acetone. The addition funnel was charged with trimethylsilylmethyl lithium (210 mL; 413.70 mmoles), which was added to the reaction mixture slowly, as to maintain an internal temperature of less than about -70°C. After addition, the resulting mixture was allowed to stir for another 20 min. The resulting mixture was worked up by addition via addition funnel of 2M HCl (250 mL; 500.00 mmoles). The resulting mixture was then allowed to warm to room temperature, then transferred to a separatory funnel and extracted with ethyl acetate (2 x 200mL). The organic phase was separated and dried (MgSO₄), and the resulting mixture filtrated and concentrated to yield the title compound as a thick oil.
A 3.0 L four-necked round bottom flask was charged with the compound prepared as in Example 13 above, (112 g, 0.23 mol) and acetonitrile (1.0 L). The resulting mixture was cooled to -20°C in an ice bath, with stirring. The methylsilane (185 mL, 1.16 mol) was added, followed by a slow addition of boron trifluoride diethyl etherate (150 mL, 1.20 mol) such that the temperature was maintained at -20°C. After the addition was complete the resulting dark orange mixture was allowed to slowly warm to 0°C. Upon completion an aqueous solution of sodium bicarbonate (200 g in 500 mL of distilled water) was added to the resulting mixture and the layers separated. The organic layer was concentrated to remove most of the acetonitrile then diluted with ethyl acetate (350 mL). The aqueous layer was saturated with sodium chloride then extracted with ethyl acetate (350 mL). The combined organic layer was washed with a saturated sodium chloride solution (100 mL), dried over sodium sulfate (135 g) and concentrated to yield the title compound as a yellow colored foam.
A 500 ml three-necked round bottom flask was charged with the compound prepared as in Example 14 above (23.56 g, 50.0 mmol), 4-methylmorpholine (27.5 ml, 250 mmol) and DMAP (0.60 g, 4.86 mmol) in THF (160 ml). The resulting yellow mixture was cooled to -10°C in an ice bath, with stirring, then acetic anhydride (23.6 ml, 250 mmol) was added dropwise, such that the temperature did not exceed 0°C. The ice bath was removed 15 minutes after the addition was complete. The resulting mixture was stirred at ambient temperature for 1.5 h, then concentrated under reduced pressure at about 30-35°C to remove most of the solvent. The resulting residue was dissolved in ethyl acetate (100-150 ml) and diluted with 1N HCl (100-150 ml). The layers were separated and the aqueous layer extracted with ethyl acetate (2 x 30 ml). The combined organic layer was washed with 100 ml each of water, a saturated bicarbonate solution and brine, then dried and concentrated to yield a damp solid. The solid was recrystallized from hot methanol (300-425 ml) to yield the title compound as a light yellow solid.
Example 16

1-(β-D-glucopyranosyl)-4-methyl-3-(5-(6-fluoro-pyrid-3-yl)-2-thienyl)methyl benzene

A 250 mL one-necked round bottom flask was charged with the compound prepared as in Example 15 above (8.52 g, 13.4 mmol) in THF (50 mL) and methanol (50 mL). To the stirred suspension was added 3N sodium hydroxide (1.2 mL, 3.60 mmol). The resulting mixture was stirred for 1 hr at ambient temperature. The volatiles were removed and the resulting residue diluted with ethyl acetate (50 mL). The layers were separated and the aqueous layer extracted with ethyl acetate (3 x 10 mL). The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to half the volume, yielding a solid precipitate. The title compound was isolated by filtration, as a cream colored solid.

The melting point, mass spec and ¹H NMR spectra, as measured for a representative sample of the compound of formula (I-K) (prepared according to the procedures as described in the Examples above) are as follows:

Melting Point: 130-132°C;
Mass Spec: m/z (LCMS API-ES) 466 (M+H);
¹H NMR (DMSO-d6): δ = 3.05-3.31 (m, 4H), 3.45 (dt, 1H, J = 5.3 Hz, J = 12.2 Hz), 3.70 (dd, 1H, J = 5.3 Hz, J = 11.4 Hz), 4.02 (d, 1H, J = 9.7 Hz), 4.28 (d, 2H, J = 3.5 Hz), 4.46 (t, 1H, J = 6.2 Hz), 4.89 (d, 1H, J = 6.2 Hz), 4.99 (d, 2H, J = 5.3 Hz), 6.93 (d, 1H, J = 3.5 Hz), 7.21 (dd, 1H, J = 3.5 Hz, J = 8.3 Hz),
7.28 (dd, 1H, J = 2.0 Hz, J = 8.3 Hz), 7.39-7.48 (m, 3H), 8.17 (ddd, 1H, J = 16.2 Hz, J = 8.3 Hz, J = 2.6 Hz), 8.46 (s, 1H)

The compound of formula (I-K), prepared as for example, described in Example 16 above, may be characterized by its powder XRD peaks, (preferably, by its powder XRD peaks with a relative intensity of greater than about 10%, more preferably, by its powder XRD peaks with a relative intensity of greater than about 25%, more preferably still, by its powder XRD peaks with a relative intensity of greater than about 35%, more preferably still, by its powder XRD peaks with a relative intensity of greater than about 50%), as listed in Table 2 below.

<table>
<thead>
<tr>
<th>Position (2° theta)</th>
<th>d-spacing (Å)</th>
<th>Relative Intensity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.22</td>
<td>8.65</td>
<td>19</td>
</tr>
<tr>
<td>12.88</td>
<td>6.87</td>
<td>18</td>
</tr>
<tr>
<td>14.58</td>
<td>6.07</td>
<td>35</td>
</tr>
<tr>
<td>16.36</td>
<td>5.41</td>
<td>41</td>
</tr>
<tr>
<td>18.36</td>
<td>4.83</td>
<td>43</td>
</tr>
<tr>
<td>18.62</td>
<td>4.76</td>
<td>85</td>
</tr>
<tr>
<td>18.76</td>
<td>4.73</td>
<td>64</td>
</tr>
<tr>
<td>19.20</td>
<td>4.62</td>
<td>88</td>
</tr>
<tr>
<td>19.84</td>
<td>4.47</td>
<td>100</td>
</tr>
<tr>
<td>20.58</td>
<td>4.31</td>
<td>61</td>
</tr>
<tr>
<td>20.76</td>
<td>4.28</td>
<td>92</td>
</tr>
<tr>
<td>21.20</td>
<td>4.19</td>
<td>45</td>
</tr>
<tr>
<td>21.88</td>
<td>4.06</td>
<td>46</td>
</tr>
<tr>
<td>22.74</td>
<td>3.91</td>
<td>31</td>
</tr>
<tr>
<td>22.96</td>
<td>3.87</td>
<td>55</td>
</tr>
<tr>
<td>23.14</td>
<td>3.84</td>
<td>31</td>
</tr>
<tr>
<td>24.44</td>
<td>3.64</td>
<td>56</td>
</tr>
<tr>
<td>24.68</td>
<td>3.60</td>
<td>45</td>
</tr>
<tr>
<td>25.06</td>
<td>3.55</td>
<td>44</td>
</tr>
<tr>
<td>25.58</td>
<td>3.48</td>
<td>23</td>
</tr>
<tr>
<td>26.24</td>
<td>3.39</td>
<td>28</td>
</tr>
<tr>
<td>27.20</td>
<td>3.28</td>
<td>53</td>
</tr>
<tr>
<td>27.66</td>
<td>3.22</td>
<td>19</td>
</tr>
<tr>
<td>28.04</td>
<td>3.18</td>
<td>23</td>
</tr>
<tr>
<td>28.24</td>
<td>3.16</td>
<td>23</td>
</tr>
<tr>
<td>29.48</td>
<td>3.03</td>
<td>40</td>
</tr>
</tbody>
</table>
Example 17

Crystallization of 1-(β-D-glucopyranosyl)-M-chloro-S-δ-(6-fluoro-S-pyridyl)-2-thienylmethylnbenzene

To a solution of 1-(2,3,4,6-tetra-O-acetyl-1-β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene (9.64 g; prepared as described in PCT Publication WO 2005/01 2326) in a mixture of methanol-tetrahydrofuran (75 ml - 75 ml) was added a solution of sodium methoxide in methanol (28%, 0.09 ml), and the resulting mixture was stirred at room temperature under argon atmosphere for 1.5 hours. The organic solvent was evaporated under reduced pressure, and thereto was added brine (200 ml).
The mixture was extracted with ethyl acetate (500 ml), and the organic layer was dried over magnesium sulfate. After being treated with activated carbon, the insoluble materials were filtered off, and the filtrate was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (60 ml), and thereto was added a seed of the crystalline of 1-((\(\beta\)-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene. The mixture was stirred at 50°C for 2.5 hours, refluxed for 45 minutes and stirred at room temperature overnight. The precipitated crystals were triturated, and the mixture was again stirred at 50°C for 30 minutes, refluxed for 45 minutes and stirred at room temperature overnight. The precipitated crystals were collected, washed with ethyl acetate (40 ml) twice and dried to yield colorless crystalline of 1-((\(\beta\)-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene (5.59 g).

mp 131-133°C.

**Example 19: Reference Example A**

![Chemical structure](image)

**STEP (1): Preparation of 1-(2,3,4,6-Tetra-O-acetyl-\(\beta\)-D-glucopyranosyl)-4-chloro-3-(5-(6-fluoro-3-pyridyl)-2-thienylmethyl)benzene**
A suspension of 1-(2,3,4,6-tetra-O-acetyl- β-D-glucopyranosylH-chloro-
3-(5-bromo-2-thienylmethyl)benzene (13.5 g; prepared as described in PCT
Publication WO 2005/01 2326), 2-fluoropyridine-5-boronic acid (Frontier
Scientific, 4.63 g), cesium fluoride (19.96 g) and

tetrakis(4-phenylphosphin)palladium(0) (2.53 g) in 1,2-dimethoxyethane (200 ml)
was refluxed for 1.5 hours. The reaction mixture was poured into a
saturated aqueous sodium hydrogen carbonate solution, and extracted with
ethyl acetate. The organic layer was washed with brine, dried over sodium
sulfate, and the solvent was evaporated under reduced pressure. The residue
was dissolved in ethyl acetate, and the mixture was treated with activated
carbon and filtered through aminosilane-treated silica gel (27 ml) pad. The
filtrate was evaporated under reduced pressure, and the residue was purified
by silica gel flash column chromatography (hexane : ethyl acetate :
dichloromethane 2 : 1 : 1) and recrystallized from methanol to yield 1-(2,3,4,6-
tetra-O-acetyl- β-D-glucopyranosyl)-4-chloro-3-(5-(6-fluoro-3-pyridyl)-2-
pyranosylH-chloro-S-[3-(5-bromo-2-thienylmethyl)benzene (8.33 g) as a colorless crystal.

mp 161-162°C
IR (Nujol) 1736, 1493, 1463, 1379, 1229, 1215 cm⁻¹
APCI-Mass m/Z 634/636 (M+H), 651/653 (M+NH₄)

1H-NMR (DMSO-de) δ 1.72 (s, 3H), 1.93 (s, 3H), 1.99 (s, 3H), 2.01 (s, 3H), 4.07-4.14 (m, 3H), 4.28 (s, 1H), 4.71 (d, J = 9.8 Hz, 1H), 4.96 (t, J = 9.5 Hz, 1H), 5.08 (t, J = 9.5 Hz, 1H), 5.36 (t, J = 9.5 Hz, 1H), 6.90 (d, J = 3.7 Hz, 1H), 7.22 (dd, J = 8.7, 2.5 Hz, 1H), 7.31-7.32 (m, 1H), 7.39 (d, J = 2 Hz, 1H), 7.44-7.48 (m, 2H), 8.14-8.18 (m, 1H), 8.45 (d, J = 2 Hz, 1H). Anal. Calcd for

C₃₀H₂₉ClFNO₉S: C, 56.83; H, 4.61 ; Cl, 5.59; F, 3.0; N, 2.21 ; S, 5.06. Found: C, 56.8; H, 4.47; Cl, 5.6; F, 2.91 ; N, 2.29 ; S, 4.93.

STEP (2): Preparation of 1-(β-D-GlucopyranosylH-chloro-S-[3-(5-bromo-2-thienylmethyl)benzene

The compound prepared as in STEP (1) above (8.33 g) was dissolved in
methanol (200 ml) - tetrahydrofuran (100 ml), thereto was added sodium
methoxide (28 % methanol solution, 5 drops), and the mixture was stirred at
room temperature for 4 hours. The solvent was evaporated under reduced
pressure, and the residue was purified by silica gel column chromatography (chloroform : methanol 100 : 0 - 88 : 12) and triturated with isopropyl ether - 2-propanol to yield 1-((β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene (4.61 g) as a colorless powder.

\[ \text{APCI-Mass } m/Z 466/468 (M+H), 483/485 (M+NH}_4 \]

\[ ^1\text{H-NMR (DMSO-de)} \delta 3.07-3.27 (m, 4H), 3.38-3.49 (m, 1H), 3.67-3.80 (m, 1H), 4.02 (d, J = 9.4 Hz, 1H), 4.27 (app d, J = 3.1 Hz, 2H), 4.33 (d, J = 4.2 Hz, 1H), 4.85 (d, J = 5.7 Hz, 1H), 4.95 (dd, J = 5.0, 3.8 Hz, 2H), 6.92 (d, J = 3.7 Hz, 1H), 7.18-7.22 (m, 1H), 7.26-7.29 (m, 1H), 7.40-7.44 (m, 3H), 8.13-8.19 (m, 1H), 8.44-8.45 (m, 1H). \]

**Example 20**

As a specific embodiment of an oral composition, 100 mg of the compound prepared as in Example 9 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0 hard gel capsule.

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.
We Claim

1. A process for the preparation of a compound of formula (I)

![Chemical Structure](image)

wherein Ring A and Ring B are one of the followings:

1. Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or

2. Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or

3. Ring A is an optionally substituted fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety -Y-(Ring B) are both on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;

X is a carbon atom;

Y is -(CH2)n-; wherein n is 1 or 2;

provided that in Ring A, X is part of an unsaturated bond;

or a pharmaceutically acceptable salt thereof, or a prodrug thereof; comprising
reacting a compound of formula (V) with a compound of formula (VI-S),
in the presence of an alkyl lithium, in an organic solvent, at a temperature in the
range of from about 0°C to about -78°C; to yield the corresponding compound
of formula (VII);

reacting the compound of formula (VII) with BF₃OEt₂, in the presence of
a thalkylsilane, in an organic solvent, to yield the corresponding compound of
formula (VIII);

reacting the compound of formula (VIII) with acetic anhydride or acetyl
chloride, in the presence of an organic base, neat or in an organic solvent, to
yield the corresponding compound of formula (IX); and
de-protecting the compound of formula (IX), to yield the corresponding compound of formula (I).

2. A process as in Claim 1, wherein the compound of formula (VI-S) is present in an amount in the range of from about 1.0 to about 1.25 molar equivalents.

3. A process as in Claim 1, wherein the alkyl lithium is (trimethylsilyl)methyl lithium and wherein the alkyl lithium is present in an amount in the range of from about 2.0 to about 2.5 molar equivalents.

4. A process as in Claim 1, wherein the alkyl lithium is added to a mixture of the compound of formula (V) and the compound of formula (VI-S) in the organic solvent.

5. A process as in Claim 1, wherein the BF$_3$OEt$_2$ is present in an amount in the range of from about 2.0 to about 6.0 molar equivalents and wherein the trialkylsilane is Et$_3$SiH and is present in an amount in the range of from about 2.0 to about 6.0 molar equivalents.

6. A process as in Claim 5, wherein the molar ratio of BF$_3$OEt$_2$ : Et$_3$SiH is about 1:1.
7. A process as in Claim 1, wherein the compound of formula (VIII) is reacted with acetic anhydride and wherein the acetic anhydride is present in an amount in the range of from about 4.5 to about 5.0 molar equivalents.

8. A process as in Claim 1, wherein the organic base is NMM.

9. A process as in Claim 1, wherein the compound of formula (VIII) is reacted with acetic anhydride in the presence of a catalytic amount of DMAP.

10. A process as in Claim 1, wherein the compound of formula (IX) is deprotected by reacting with a base.

11. A process for the preparation of a compound of formula (I-S) or a pharmaceutically acceptable salt or a prodrug thereof; comprising
reacting a compound of formula (V-S), with a compound of formula (VI-S), in the presence of an alkyl lithium, in an organic solvent, at a temperature in the range of from about 0°C to about -78°C, to yield the corresponding compound of formula (VII-S);

reacting the compound of formula (VII-S) with BF$_3$OEt$_2$, in the presence of a trialkylsilane, in an organic solvent, to yield the corresponding compound of formula (VIII-S);

reacting a compound of formula (V-S), with a compound of formula (VI-S), in the presence of an alkyl lithium, in an organic solvent, at a temperature in the range of from about 0°C to about -78°C, to yield the corresponding compound of formula (VII-S);
reacting the compound of formula (VIII-S) with acetic anhydride or acetyl chloride, in the presence of an organic base, neat or in an organic solvent, to yield the corresponding compound of formula (IX-S); and

de-protecting the compound of formula (IX-S) to yield the corresponding compound of formula (I-S).

12. A process as in Claim 11, wherein the compound of formula (VI-S) is present in an amount in the range of from about 1.0 to about 1.25 molar equivalents.

13. A process as in Claim 11, wherein the alkyl lithium is (thmethylsilyl)methyl lithium and wherein the alkyl lithium is present in an amount in the range of from about 2.0 to about 2.5 molar equivalents.

14. A process as in Claim 11, wherein the alkyl lithium is added to a mixture of the compound of formula (V-S) and the compound of formula (VI-S) in the organic solvent.

15. A process as in Claim 11, wherein the BF$_3$OEt$_2$ is present in an amount in the range of from about 2.0 to about 6.0 molar equivalents and wherein the trialkysilane is Et$_3$SiH and is present in an amount in the range of from about 2.0 to about 6.0 molar equivalents.

16. A process as in Claim 15, wherein the molar ratio of BF$_3$OEt$_2$ : Et$_3$SiH is about 1:1.
17. A process as in Claim 11, wherein the compound of formula (VIII-S) is reacted with acetic anhydride and wherein the acetic anhydride is present in an amount in the range of from about 4.5 to about 5.0 molar equivalents.

18. A process as in Claim 11, wherein the organic base is NMM.

19. A process as in Claim 11, wherein the compound of formula (VIII-S) is reacted with acetic anhydride in the presence of a catalytic amount of DMAP.

20. A process as in Claim 11, wherein the compound of formula (IX-S) is further slurried in methanol and filtered.

21. A process as in Claim 11, wherein the compound of formula (IX-S) is deprotected by reacting with a base.

22. A process for the recrystallization of a compound of formula (I-S)

\[
\text{CH}_3
\]

\[
\text{O}
\]

\[
\text{O}
\]

\[
\text{OH}
\]

\[
\text{OH}
\]

\[
\text{F}
\]

comprising

(a) dissolving the compound of formula (I-S) in an organic solvent to yield mixture A;

(b) heating mixture A to a temperature in the range of from about 25°C to about 45°C to yield mixture B;

(c) adding between about 1.0 and about 2.0 molar equivalents of water to mixture B to yield mixture C;

(d) adding heptane to mixture C, to yield a suspension of the compound of formula (I-S); and
(e) isolating the compound of formula (I-S).

23. A process as in Claim 22, wherein the organic solvent is ethyl acetate.

24. A process as in Claim 22, wherein mixture A is heated to a temperature in the range of from about 30°C to about 35°C.

25. A process as in Claim 22, wherein about 1.5 molar equivalents of water are added to mixture B.

26. A process as in Claim 23, wherein heptane is added to mixture C in an amount which yields a final volume:volume ratio of ethyl acetate:heptane of about 1.2:1.0.

27. A process for the preparation of a compound of formula (I-K) or a pharmaceutically acceptable salt thereof; comprising

![Diagram](V-K) → ![Diagram](VI-S)
reacting a compound of formula (V-K), with a compound of formula (VI-S), in the presence of an alkyl lithium, in an organic solvent, at a temperature in the range of from about 0°C to about -78°C, to yield the corresponding compound of formula (VII-K);

deprotecting the compound of formula (VII-K) to yield the corresponding compound of formula (X-K);
reacting the compound of formula (X-K) with \( BF_3\text{OEt}_2 \), in the presence of a thalkylsilane, in an organic solvent, to yield the corresponding compound of formula (VIII-K):

![Diagram of chemical reaction]

5 reacting the compound of formula (VIII-K) with acetic anhydride or acetyl chloride, in the presence of an organic base, neat or in an organic solvent, to yield the corresponding compound of formula (IX-K); and

![Diagram of chemical reaction]

de-protecting the compound of formula (IX-K) to yield the corresponding compound of formula (I-K).

28. A process as in Claim 27, wherein the compound of formula (VI-S) is present in an amount in the range of from about 1.0 to about 1.25 molar equivalents.

29. A process as in Claim 27, wherein the alkyl lithium is (thmethylsilyl)methyl lithium and wherein the alkyl lithium is present in an amount in the range of from about 2.0 to about 2.5 molar equivalents.
30. A process as in Claim 27, wherein the alkyl lithium is added to a mixture of the compound of formula (V-K) and the compound of formula (VI-S) in the organic solvent.

31. A process as in Claim 27, wherein the BF₃OEt₂ is present in an amount in the range of from about 2.0 to about 6.0 molar equivalents and wherein the trialkylsilane is Et₃SiH and is present in an amount in the range of from about 2.0 to about 6.0 molar equivalents.

32. A process as in Claim 31, wherein the molar ratio of BF₃OEt₂ : Et₃SiH is about 1:1.

33. A process as in Claim 27, wherein the compound of formula (VIII-K) is reacted with acetic anhydride and wherein the acetic anhydride is present in an amount in the range of from about 4.5 to about 5.0 molar equivalents.

34. A process as in Claim 27, wherein the organic base is NMM.

35. A process as in Claim 27, wherein the compound of formula (VIII-K) is reacted with acetic anhydride in the presence of a catalytic amount of DMAP.

36. A process as in Claim 27, wherein the compound of formula (IX-K) is deprotected by reacting with a base.

37. A crystalline form of a compound of formula (I-S)
characterized by the following X-ray diffraction pattern peaks:

<table>
<thead>
<tr>
<th>Position (2° theta)</th>
<th>d-spacing (Å)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.9</td>
<td>22.8</td>
</tr>
<tr>
<td>8.0</td>
<td>11.1</td>
</tr>
<tr>
<td>9.7</td>
<td>9.2</td>
</tr>
<tr>
<td>10.9</td>
<td>8.1</td>
</tr>
<tr>
<td>13.0</td>
<td>6.8</td>
</tr>
<tr>
<td>13.9</td>
<td>6.4</td>
</tr>
<tr>
<td>15.5</td>
<td>5.7</td>
</tr>
<tr>
<td>15.6</td>
<td>5.7</td>
</tr>
<tr>
<td>15.9</td>
<td>5.6</td>
</tr>
<tr>
<td>16.2</td>
<td>5.5</td>
</tr>
<tr>
<td>17.3</td>
<td>5.1</td>
</tr>
<tr>
<td>18.3</td>
<td>4.9</td>
</tr>
<tr>
<td>18.7</td>
<td>4.7</td>
</tr>
<tr>
<td>18.8</td>
<td>4.7</td>
</tr>
<tr>
<td>19.1</td>
<td>4.6</td>
</tr>
<tr>
<td>19.4</td>
<td>4.6</td>
</tr>
<tr>
<td>20.3</td>
<td>4.4</td>
</tr>
<tr>
<td>20.9</td>
<td>4.3</td>
</tr>
<tr>
<td>21.1</td>
<td>4.2</td>
</tr>
<tr>
<td>21.8</td>
<td>4.1</td>
</tr>
<tr>
<td>22.5</td>
<td>3.9</td>
</tr>
<tr>
<td>22.7</td>
<td>3.9</td>
</tr>
<tr>
<td>23.2</td>
<td>3.8</td>
</tr>
<tr>
<td>23.4</td>
<td>3.8</td>
</tr>
<tr>
<td>25.1</td>
<td>3.6</td>
</tr>
<tr>
<td>25.7</td>
<td>3.5</td>
</tr>
<tr>
<td>26.3</td>
<td>3.4</td>
</tr>
<tr>
<td>26.8</td>
<td>3.3</td>
</tr>
<tr>
<td>27.3</td>
<td>3.3</td>
</tr>
</tbody>
</table>

38. A process for the preparation of the crystalline form of Claim 37, comprising

(a) dissolving a compound of formula (I-S)
in ethyl acetate to yield mixture A;
(b) heating mixture A to a temperature in the range of from about 30°C
to about 35°C to yield mixture B;
(c) adding about 1.5 molar equivalents of water to mixture B to yield
mixture C;
(d) adding heptane to mixture C, to yield a suspension of the compound
of formula (I-S); wherein the heptane is added to mixture C in an amount which
yields a final volume:volume ratio of ethyl acetate:heptane of about 1.2:1.0; and
(e) isolating the compound of formula (I-S).

39. A crystalline form of a 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-
pyridyl)-2-thienylmethyl]benzene.

40. A crystalline form of a compound of formula (I-K)
characterized by the following powder x-ray diffraction 2Θ values measured using CuKa radiation: 14.60 ± 0.2, 16.38 ± 0.2, 18.62 ± 0.2, 19.20 ± 0.2, 19.86 ± 0.2 and 20.76 ± 0.2.

41. A crystalline form of 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene, having substantially the same powder X-ray diffraction pattern as set out in Figure 2.

42. A crystalline form of 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene, having substantially the same powder X-ray diffraction pattern as set out in Figure 3.

43. A crystalline form of 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene, having substantially the same infra-red spectrum, as set out in Figure 4.

44. A crystalline form of 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene, having substantially the same infra-red spectrum, as set out in Figure 5.

45. A crystalline form of a compound of formula (I-K)

\[
\begin{align*}
\text{Cl} & \quad \text{S} \\
\text{F} & \quad \text{N} \\
\text{HO} & \quad \text{OH} \\
\text{OH} & \quad \text{OH}
\end{align*}
\]

(characterized by the following X-ray diffraction pattern peaks:

<table>
<thead>
<tr>
<th>Position (2° theta)</th>
<th>d-spacing (Å)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.22</td>
<td>8.65</td>
</tr>
<tr>
<td>12.88</td>
<td>6.87</td>
</tr>
</tbody>
</table>
46. A process for the preparation of a crystalline form of 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene, comprising (a) forming a solution of 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene; and (b) crystallizing the crystalline form from the solution by precipitation or recrystallization.
47. A pharmaceutical composition comprising a therapeutically effective amount of a crystalline form of 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene and a pharmaceutically acceptable carrier.

48. A method for treating or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension, comprising administering to a subject in need thereof, a therapeutically effective amount of a crystalline form of 1-(β-D-glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene.

49. A compound of formula (IX-S):

![Chemical Structure](image)

(IX-S)

or a salt thereof.
Representative XRD pattern for the crystalline form of the compound of formula (I-S)
FIG. 2

Representative XRD pattern for the crystalline form of the compound of formula (I-K)
FIG. 3

Representative XRD pattern for the crystalline form of the compound of formula (I-K)
FIG. 4

Representative infra-red spectra in mineral oil, for the crystalline form of the compound of formula (I-K)
FIG. 5

Representative infra-red spectra in mineral oil, measured for the crystalline form of the compound of formula (I-K).
INTERNATIONAL SEARCH REPORT

INTERNATIONAL APPLICATION No.
PCT/US08/75700

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8)- A61K 31/381, A61P 3/00, C07D 409/10 (2008.04)
USPC - 514/43; 514/443, 514/444, 536/28.6

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
USPC - 514/43; 514/443, 514/444, 536/28.6
IPC(8) - A61K 31/381, A61P 3/00, C07D 409/10 (2008.04)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC - 514/43; 514/443, 514/444, 536/28.6
IPC(8) - A61K 31/381, A61P 3/00, C07D 409/10 (2008.04) (text search)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Electronic Databases Searched: USPTO WEST (PGPUB, EPAB, JPAB, USPT), Google Patent, Google Scholar
Search Terms Used: glucopyranosyl, synthesis or preparation, XRD or X-ray, trimethylsilyl, lithium, thienylmethyl and benzene

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
X WO 2005/012326 A1 (NOMURA et al.) 10 February 2005 (10.02.2005), entire document especially pages abstract; table 1 and 5; page 69-70; 89-90; 107; page 70, in 01-08; page 50, in 07-09 1-36, 46-49
Y US 5,945,533 A (KOMETANI et al.) 31 August 1999 (31.08.1999), especially figure 2 37-45

Further documents are listed in the continuation of Box C.

* Special categories of cited documents
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search 18 November 2008 (18.11.2008)
Date of mailing of the international search report 08 DEC 2008

Lee W. Young
Authorized officer

Form PCT/ISA/210 (second sheet) (April 2007)